Definitive endoderm

ABSTRACT

Disclosed herein are cell cultures comprising definitive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified definitive endoderm cells as well as methods for enriching, isolating and purifying definitive endoderm cells from other cell types.

RELATED APPLICATIONS

This application is a continuation of and claims priority under 35U.S.C. §120 to U.S. patent application Ser. No. 10/584,338, entitledDEFINITIVE ENDODERM, filed Jan. 9, 2007, which is a United Statesnational phase application under 35 U.S.C. §371 of PCT ApplicationNumber PCT/US2004/043696, entitled DEFINITIVE ENDODERM, filed Dec. 23,2004, which was published in English as PCT Application PublicationNumber WO2005/063971 on Jul. 14, 2005, and which is a nonprovisionalapplication of and claims priority to U.S. Provisional PatentApplication No. 60/587,942, entitled CHEMOKINE CELL SURFACE RECEPTOR FORTHE ISOLATION OF DEFINITIVE ENDODERM, filed Jul. 14, 2004, U.S.Provisional Patent Application No. 60/586,566, entitled CHEMOKINE CELLSURFACE RECEPTOR FOR THE ISOLATION OF DEFINITIVE ENDODERM, filed Jul. 9,2004, and U.S. Provisional Patent Application No. 60/532,004, entitledDEFINITIVE ENDODERM, filed Dec. 23, 2003. The disclosure of each of theabove-listed priority applications is incorporated herein by referencein its entirety.

FIELD OF THE INVENTION

The present invention relates to the fields of medicine and cellbiology. In particular, the present invention relates to compositionscomprising mammalian definitive endoderm cells and methods of making,isolating and using such cells.

BACKGROUND

Human pluripotent stem cells, such as embryonic stem (ES) cells andembryonic germ (EG) cells, were first isolated in culture withoutfibroblast feeders in 1994 (Bongso et al., 1994) and with fibroblastfeeders (Hogan, 1997). Later, Thomson, Reubinoff and Shamblottestablished continuous cultures of human ES and EG cells usingmitotically inactivated mouse feeder layers (Reubinoff et al., 2000;Shamblott et al., 1998; Thomson et al., 1998).

Human ES and EG cells (hESCs) offer unique opportunities forinvestigating early stages of human development as well as fortherapeutic intervention in several disease states, such as diabetesmellitus and Parkinson's disease. For example, the use ofinsulin-producing 3-cells derived from hESCs would offer a vastimprovement over current cell therapy procedures which utilize cellsfrom donor pancreases. However, presently it is not known how togenerate an insulin-producing β-cell from hESCs. As such, current celltherapy treatments for diabetes mellitus, which utilize islet cells fromdonor pancreases, are limited by the scarcity of high quality isletcells needed for transplant. Cell therapy for a single Type I diabeticpatient requires a transplant of approximately 8×10⁸ pancreatic isletcells. (Shapiro et al., 2000; Shapiro et al., 2001a; Shapiro et al.,2001b). As such, at least two healthy donor organs are required toobtain sufficient islet cells for a successful transplant. HESCs offer asource of starting material from which to develop substantial quantitiesof high quality differentiated cells for human cell therapies.

Two properties that make hESCs uniquely suited to cell therapyapplications are pluripotence and the ability to maintain these cells inculture for prolonged periods without accumulation of genetic changes.Pluripotency is defined by the ability of hESCs to differentiate toderivatives of all 3 primary germ layers (endoderm, mesoderm, ectoderm)which, in turn, form all cell somatic types of the mature organism inaddition to extraembryonic tissues (e.g. placenta) and germ cells.Although pluripotency imparts extraordinary utility upon hESCs, thisproperty also poses unique challenges for the study and manipulation ofthese cells and their derivatives. Owing to the large variety of celltypes that may arise in differentiating hESC cultures, the vast majorityof cell types are produced at very low efficiencies. Additionally,success in evaluating production of any given cell type dependscritically on defining appropriate markers. Achieving efficient,directed differentiation is of great importance for therapeuticapplication of hESCs.

In order to use hESCs as a starting material to generate cells that areuseful in cell therapy applications, it would be advantageous toovercome the foregoing problems. For example, in order to achieve thelevel of cellular material required for islet cell transplantationtherapy, it would be advantageous to efficiently direct hESCs toward thepancreatic islet/β-cell lineage at the very earliest stages ofdifferentiation.

In addition to efficient direction of the differentiation process, itwould also be beneficial to isolate and characterize intermediate celltypes along the differentiation pathway towards the pancreaticislet/β-cell lineage and to use such cells as appropriate lineageprecursors for further steps in the differentiation.

SUMMARY OF THE INVENTION

Some embodiments of the present invention relate to cell culturescomprising definitive endoderm cells, wherein the definitive endodermcells are multipotent cells that can differentiate into cells of the guttube or organs derived from the gut tube. In accordance with certainembodiments, the definitive endoderm cells are mammalian cells, and in apreferred embodiment, the definitive endoderm cells are human cells. Insome embodiments of the present invention, definitive endoderm cellsexpress or fail to significantly express certain markers. In someembodiments, one or more markers selected from SOX17, CXCR4, MIXL1,GATA4, HNF3b, GSC, FGF17, VWF, CALCR, FOXQ1, CMKOR1 and CRIP1 areexpressed in definitive endoderm cells. In other embodiments, one ormore markers selected from OCT4, alpha-fetoprotein (AFP), Thrombomodulin(TM), SPARC and SOX7 are not significantly expressed in definitiveendoderm cells.

In accordance with other embodiments of the present invention, methodsof producing definitive endoderm from pluripotent cells are described.In some embodiments, pluripotent cells are derived from a morula. Insome embodiments, pluripotent stem cells are stem cells. Stem cells usedin these methods can include, but are not limited to, embryonic stemcells. Embryonic stem cells can be derived from the embryonic inner cellmass or from the embryonic gonadal ridges. Embryonic stem cells canoriginate from a variety of animal species including, but not limitedto, various mammalian species including humans. In a preferredembodiment, human embryonic stem cells are used to produce definitiveendoderm.

In some embodiments of the present invention, one or more growth factorsare used in the differentiation process from pluripotent cell todefinitive endoderm cell. The one or more growth factors used in thedifferentiation process can include growth factors from the TGFβsuperfamily. In such embodiments, the one or more growth factorscomprise the Nodal/Activin and/or the BMP subgroups of the TGFβsuperfamily of growth factors. In some embodiments, the one or moregrowth factors are selected from the group consisting of Nodal, ActivinA, Activin B, BMP4, Wnt3a or combinations of any of these growthfactors.

Embodiments of the present invention also relate to populations of cellsenriched in definitive endoderm cells. In certain embodiments, thedefinitive endoderm cells are isolated or substantially purified. Insome embodiments, the isolated or substantially purified definitiveendoderm cells express the SOX17 and/or the CXRC4 marker to a greaterextent than the OCT4, AFP, TM, SPARC and/or SOX7 markers.

Methods for enriching a cell population with definitive endoderm arealso contemplated. In some embodiments, definitive endoderm cells can beisolated or substantially purified from a mixed cell population bycontacting the cells with a reagent that binds to a molecule that ispresent on the surface of definitive endoderm cells but which is notpresent on the surface of other cells in the mixed cell population, andthen isolating the cells bound to the reagent. In certain embodiments,the molecule that is present on the surface of definitive endoderm cellsis CXCR4.

Still other embodiments of the present invention relate to CXCR4antibodies, SDF-1 ligands or other ligands for CXCR4 can be used toobtain definitive endoderm cells in an enriched, isolated orsubstantially purified form. For example, a CXCR4 antibody, an SDF-1ligand or another ligand for CXCR4 can be used as a reagent in a method,such as affinity-based separation or magnetic-based separation, toenrich, isolate or substantially purify preparations of definitiveendoderm cells which bind to the reagent.

Other embodiments of the invention described herein relate tocompositions, such as cell cultures, which comprise pluripotent cellsand definitive endoderm cells. In certain embodiments, the cell culturescomprise both stem cells and definitive endoderm cells. The number ofstem cells present in such cultures can be greater than, equal to orless than the number of definitive endoderm cells in the culture. Insome embodiments, the stem cells are human embryonic stem cells. Incertain embodiments the hESCs are maintained on a feeder layer. In suchembodiments, the feeder layer cells can be cells, such as fibroblasts,which are obtained from humans, mice or any other suitable organism.

In some embodiments of the present invention, the compositionscomprising definitive endoderm cells and hESCs also includes one or moregrowth factors. Such growth factors can include growth factors from theTGFβ superfamily. In such embodiments, the one or more growth factorscomprise the Nodal/Activin and/or the BMP subgroups of the TGF3superfamily of growth factors. In some embodiments, the one or moregrowth factors are selected from the group consisting of Nodal, ActivinA, Activin B, BMP4, Wnt3a or combinations of any of these growthfactors.

Other embodiments of the present inventions are described with referenceto the numbered paragraphs below:

1. A cell culture comprising human cells wherein at least about 10% ofsaid human cells are definitive endoderm cells, said definitive endodermcells being multipotent cells that can differentiate into cells of thegut tube or organs derived therefrom.

2. The cell culture of paragraph 1, wherein at least about 50% of saidhuman cells are definitive endoderm cells.

3. The cell culture of paragraph 1, wherein at least about 80% of saidhuman cells are definitive endoderm cells.

4. The cell culture of paragraph 1, wherein said definitive endodermcells express a marker selected from the group consisting of SOX17 andCXCR4.

5. The cell culture of paragraph 4, wherein the expression of a markerselected from the group consisting of SOX17 and CXCR4 is greater thanthe expression of a marker selected from the group consisting of OCT4,alpha-fetoprotein (AFP), Thrombomodulin (TM), SPARC and SOX7 in saiddefinitive endoderm cells.

6. The cell culture of paragraph 4, wherein said definitive endodermcells do not express a marker selected from the group consisting ofOCT4, AFP, TM, SPARC and SOX7.

7. The cell culture of paragraph 4, wherein said definitive endodermcells express a marker selected from the group consisting of MIXL1,GATA4 and HNF3b.

8. The cell culture of paragraph 4, wherein said definitive endodermcells express a marker selected from the group consisting of FGF17, VWF,CALCR, FOXQ1, CMKOR1 and CRIP1.

9. The cell culture of paragraph 1, wherein said definitive endodermcells express SOX17 and CXCR4.

10. The cell culture of paragraph 9, wherein the expression of SOX17 andCXCR4 is greater than the expression of OCT4, AFP, TM, SPARC and SOX7 insaid definitive endoderm cells.

11. The cell culture of paragraph 9, wherein said definitive endodermcells do not express OCT4, AFP, TM, SPARC and SOX7.

12. The cell culture of paragraph 9, wherein said definitive endodermcells express MIXL1, GATA4 and HNF3b.

13. The cell culture of paragraph 9, wherein said definitive endodermcells express a marker selected from the group consisting of FGF17, VWF,CALCR, FOXQ1, CMKOR1 and CRIP1.

14. The cell culture of paragraph 1, wherein at least about 2 definitiveendoderm cells are present for about every 1 pluripotent cell in saidcell culture.

15. The cell culture of paragraph 14, wherein said pluripotent cellcomprises an embryonic stem cell.

16. The cell culture of paragraph 15, wherein said embryonic stem cellis derived from a tissue selected from the group consisting of themorula, the inner cell mass (ICM) of an embryo and the gonadal ridges ofan embryo.

17. The cell culture of paragraph 1 further comprising a medium whichcomprises less than about 10% serum.

18. The cell culture of paragraph 1 further comprising a growth factorof the Nodal/Activin subgroup of the TGFβ superfamily.

19. The cell culture of paragraph 1, further comprising a growth factorselected from the group consisting of Nodal, Activin A, Activin B andcombinations thereof.

20. A cell population comprising cells wherein at least about 90% ofsaid cells are human definitive endoderm cells, said human definitiveendoderm cells being multipotent cells that can differentiate into cellsof the gut tube or organs derived therefrom.

21. The cell population of paragraph 20, wherein at least about 95% ofsaid cells are human definitive endoderm cells.

22. The cell population of paragraph 20, wherein at least about 98% ofsaid cells are human definitive endoderm cells.

23. The cell population of paragraph 20, wherein said human definitiveendoderm cells express a marker selected from the group consisting ofSOX17 and CXCR4.

24. The cell population of paragraph 23, wherein the expression of amarker selected from the group consisting of SOX17 and CXCR4 is greaterthan the expression of a marker selected from the group consisting ofOCT4, AFP, TM, SPARC and SOX7 in said human definitive endoderm cells.

25. The cell population of paragraph 23, wherein said human definitiveendoderm cells do not express a marker selected from the groupconsisting of OCT4, AFP, TM, SPARC and SOX7.

26. The cell population of paragraph 23, wherein said human definitiveendoderm cells express a marker selected from the group consisting ofMIXL1, GATA4 and HNF3b.

27. The cell population of paragraph 23, wherein said definitiveendoderm cells express a marker selected from the group consisting ofFGF17, VWF, CALCR, FOXQ1, CMKOR1 and CRIP1.

28. The cell population of paragraph 20, wherein said human definitiveendoderm cells express SOX17 and CXCR4.

29. The cell population of paragraph 28, wherein the expression of SOX17and CXCR4 is greater than the expression of OCT4, AFP, TM, SPARC andSOX7 in said human definitive endoderm cells.

30. The cell population of paragraph 28, wherein said human definitiveendoderm cells do not express OCT4, AFP, TM, SPARC and SOX7.

31. The cell population of paragraph 28, wherein said human definitiveendoderm cells express MIXL1, GATA4 and HNF3b.

32. The cell population of paragraph 28, wherein said definitiveendoderm cells express a marker selected from the group consisting ofFGF17, VWF, CALCR, FOXQ1, CMKOR1 and CRIP1.

33. The cell population of paragraph 20, wherein at least about 2 humandefinitive endoderm cells are present for about every 1 pluripotent cellin said cell population.

34. The cell population of paragraph 33, wherein said pluripotent cellcomprises an embryonic stem cell.

35. The cell population of paragraph 34, wherein said embryonic stemcell is derived from a tissue selected from the morula, the ICM of anembryo and the gonadal ridges of an embryo.

36. A method of producing definitive endoderm cells, said methodcomprising the steps of:

obtaining a cell population comprising pluripotent human cells;

providing said cell population with at least one growth factor of theTGFβ superfamily in an amount sufficient to promote differentiation ofsaid pluripotent cells to definitive endoderm cells, said definitiveendoderm cells being multipotent cells that can differentiate into cellsof the gut tube or organs derived therefrom; and

allowing sufficient time for definitive endoderm cells to form, whereinsaid sufficient time for definitive endoderm cells to form has beendetermined by detecting the presence of definitive endoderm cells insaid cell population.

37. The method of paragraph 36, wherein at least about 10% of saidpluripotent cells differentiate into definitive endoderm cells.

38. The method of paragraph 36, wherein at least about 50% of saidpluripotent cells differentiate into definitive endoderm cells.

39. The method of paragraph 36, wherein at least about 70% of saidpluripotent cells differentiate into definitive endoderm cells.

40. The method of paragraph 36, wherein at least about 80% of saidpluripotent cells differentiate into definitive endoderm cells.

41. The method of paragraph 36, wherein detecting the presence ofdefinitive endoderm cells in said cell population comprises detectingthe expression of at least one marker selected from the group consistingof SOX17 and CXCR4 and at least one marker from the group consisting ofOCT4, AFP, TM, SPARC and SOX7 in cells of said cell population, whereinthe expression of a marker selected from the group consisting of SOX17and CXCR4 is greater than the expression of a marker selected from thegroup consisting of OCT4, AFP, TM, SPARC and SOX7 in said definitiveendoderm cells.

42. The method of paragraph 36, wherein detecting the presence ofdefinitive endoderm cells in said cell population comprises detectingthe expression of at least one marker selected from the group consistingof SOX17 and CXCR4 and at least one marker from the group consisting ofAFP, TM, and SOX7 in cells of said cell population, wherein theexpression of a marker selected from the group consisting of SOX17 andCXCR4 is greater than the expression of a marker selected from the groupconsisting of AFP, TM, and SOX7 in said definitive endoderm cells.

43. The method of paragraph 42, wherein the expression of at least oneof said markers is determined by Q-PCR.

44. The method of paragraph 42, wherein the expression of at least oneof said markers is determined by immunocytochemistry.

45. The method of paragraph 36, wherein detecting the presence ofdefinitive endoderm cells in said cell population comprises detectingthe expression of at least one marker selected from the group consistingof FGF17, VWF, CALCR, FOXQ1, CMKOR1 and CRIP1 and at least one markerfrom the group consisting of OCT4, AFP, TM, SPARC and SOX7 in cells ofsaid cell population, wherein the expression of a marker selected fromthe group consisting of FGF17, VWF, CALCR, FOXQ1, CMKOR1 and CRIP1 isgreater than the expression of a marker selected from the groupconsisting of OCT4, AFP, TM, SPARC and SOX7 in said definitive endodermcells.

46. The method of paragraph 36, wherein said at least one growth factoris of the Nodal/Activin subgroup of the TGFβ superfamily.

47. The method of paragraph 46, wherein said at least one growth factoris selected from the group consisting of Nodal Activin A, Activin B andcombinations thereof.

48. The method of paragraph 47, wherein said at least one growth factoris Nodal.

49. The method of paragraph 47, wherein said at least one growth factoris Activin A.

50. The method of paragraph 47, wherein said at least one growth factoris Activin B.

51. The method of paragraph 36, wherein a plurality of growth factors ofthe TGFβ superfamily is provided.

52. The method of paragraph 51, wherein said plurality of growth factorscomprises Nodal Activin A and Activin B.

53. The method of paragraph 36, wherein said at least one growth factoris provided in a concentration of at least about 10 ng/ml.

54. The method of paragraph 36, wherein said at least one growth factoris provided in a concentration of at least about 100 ng/ml.

55. The method of paragraph 36, wherein said at least one growth factoris provided in a concentration of at least about 500 ng/ml.

56. The method of paragraph 36, wherein said at least one growth factoris provided in a concentration of at least about 1000 ng/ml.

57. The method of paragraph 36, wherein said at least one growth factoris provided in a concentration of at least about 5000 ng/ml.

58. The method of paragraph 36, wherein said cell population is grown ina medium comprising less than about 10% serum.

59. The method of paragraph 36, wherein said pluripotent cells comprisestem cells.

60. The method of paragraph 59, wherein said pluripotent cells compriseembryonic stem cells.

61. The method of paragraph 60, wherein said embryonic stem cells arederived from a tissue selected from the group consisting of the morula,the ICM of an embryo and the gonadal ridges of an embryo.

62. A definitive endoderm cell produced by the method of paragraph 36.

63. A method of producing a cell population enriched in definitiveendoderm cells, said method comprising the steps of:

differentiating cells in a population of pluripotent human cells so asto produce definitive endoderm cells, said definitive endoderm cellsbeing multipotent cells that can differentiate into cells of the guttube or organs derived therefrom;

providing to said cell population a reagent which binds to a markerexpressed in said definitive endoderm cells but which is notsubstantially expressed in other cell types present in said cellpopulation; and

separating said definitive endoderm cells bound to said reagent fromsaid other cell types present in said cell population, thereby producinga cell population enriched in definitive endoderm cells.

64. The method of paragraph 63, wherein the differentiating step furthercomprises obtaining a cell population comprising pluripotent humancells, providing said cell population with at least one growth factor ofthe TGFβ superfamily in an amount sufficient to promote differentiationof said pluripotent cells to definitive endoderm cells, said definitiveendoderm cells being multipotent cells that can differentiate into cellsof the gut tube or organs derived therefrom, and allowing sufficienttime for definitive endoderm cells to form, wherein said sufficient timefor definitive endoderm cells to form has been determined by detectingthe presence of definitive endoderm cells in said cell population.

65. The method of paragraph 63, wherein detecting comprises detectingthe expression of at least one marker selected from the group consistingof SOX17 and CXCR4 and at least one marker from the group consisting ofOCT4, AFP, TM, SPARC and SOX7 in cells of said cell population, whereinthe expression of a marker selected from the group consisting of SOX17and CXCR4 is greater than the expression of a marker selected from thegroup consisting of OCT4, AFP, TM, SPARC and SOX7 in said definitiveendoderm cells.

66. The method of paragraph 63, wherein detecting comprises detectingthe expression of at least one marker selected from the group consistingof SOX17 and CXCR4 and at least one marker from the group consisting ofAFP, TM, and SOX7 in cells of said cell population, wherein theexpression of a marker selected from the group consisting of SOX17 andCXCR4 is greater than the expression of a marker selected from the groupconsisting of AFP, TM, and SOX7 in said definitive endoderm cells.

67. The method of paragraph 63, wherein detecting comprises detectingthe expression of at least one marker selected from the group consistingof FGF17, VWF, CALCR, FOXQ1, CMKOR1 and CRIP1 and at least one markerfrom the group consisting of OCT4, AFP, TM, SPARC and SOX7 in cells ofsaid cell population, wherein the expression of a marker selected fromthe group consisting of FGF17, VWF, CALCR, FOXQ1, CMKOR1 and CRIP1 isgreater than the expression of a marker selected from the groupconsisting of OCT4, AFP, TM, SPARC and SOX7 in said definitive endodermcells.

68. The method of paragraph 63, wherein at least about 95% of said cellsare definitive endoderm cells.

69. The method of paragraph 63, wherein at least about 98% of said cellsare definitive endoderm cells.

70. The method of paragraph 63, wherein said marker is CXCR4.

71. The method of paragraph 63, wherein said reagent is an antibody

72. The method of paragraph 71, wherein said antibody has affinity forCXCR4.

73. An enriched population of definitive endoderm cells produced by themethod of paragraph 63.

74. The cell culture of any one of paragraphs 4 or 9, wherein saiddefinitive endoderm cells do not significantly express a marker selectedfrom the group consisting of OCT4, AFP, TM, SPARC and SOX7.

75. The cell population of any one of paragraphs 23 or 28, wherein saiddefinitive endoderm cells do not significantly express a marker selectedfrom the group consisting of OCT4, AFP, TM, SPARC and SOX7.

It will be appreciated that the methods and compositions described aboverelate to cells cultured in vitro. However, the above-described in vitrodifferentiated cell compositions may be used for in vivo applications.

Additional embodiments of the present inventions may also be found inU.S. Provisional Patent Application No. 60/532,004, entitled DEFINITIVEENDODERM, filed Dec. 23, 2003; U.S. Provisional Patent Application No.60/586,566, entitled CHEMOKINE CELL SURFACE RECEPTOR FOR THE ISOLATIONOF DEFINITIVE ENDODERM, filed Jul. 9, 2004; and U.S. Provisional PatentApplication No. 60/587,942, entitled CHEMOKINE CELL SURFACE RECEPTOR FORTHE ISOLATION OF DEFINITIVE ENDODERM, filed Jul. 14, 2004, thedisclosures of which are incorporated herein by reference in theirentireties.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic of a proposed differentiation pathway for theproduction of beta-cells from hESCs. The first step in the pathwaycommits the ES cell to the definitive endoderm lineage and representsone of the earliest known steps in the further differentiation of EScells to pancreatic endoderm, endocrine endoderm, or islet/beta-cell.Some factors useful for mediating this transition are members of theTGFβ family which include, but are not limited to, activins, nodals andBMPs. Exemplary markers for defining the definitive endoderm target cellare SOX17, GATA4, HNF3b, MIX1 and CXCR4.

FIG. 2 is a diagram of the human SOX17 cDNA which displays the positionsof conserved motifs and highlights the region used for the immunizationprocedure by GENOVAC.

FIG. 3 is a relational dendrogram illustrating that SOX17 is mostclosely related to SOX7 and somewhat less to SOX18. The SOX17 proteinsare more closely related among species homologs than to other members ofthe SOX group F subfamily within the same species.

FIG. 4 is a Western blot probed with the rat anti-SOX17 antibody. Thisblot demonstrates the specificity of this antibody for human SOX17protein over-expressed in fibroblasts (lane 1) and a lack ofimmunoreactivity with EGFP (lane 2) or the most closely related SOXfamily member, SOX7 (lane 3).

FIGS. 5A-B are micrographs showing a cluster of SOX17⁺ cells thatdisplay a significant number of AFP⁺ co-labeled cells (A). This is instriking contrast to other SOX17⁺ clusters (B) where little or no AFP⁺cells are observed.

FIGS. 6A-C are micrographs showing parietal endoderm and SOX17. Panel Ashows immunocytochemistry for human Thrombomodulin (TM) protein locatedon the cell surface of parietal endoderm cells in randomlydifferentiated cultures of hES cells. Panel B is the identical fieldshown in A double-labeled for TM and SOX17. Panel C is the phasecontrast image of the same field with DAPI labeled nuclei. Note thecomplete correlation of DAPI labeled nuclei and SOX17 labeling.

FIGS. 7A-B are bar charts showing SOX17 gene expression by quantitativePCR (Q-PCR) and anti-SOX17 positive cells by SOX17-specific antibody.Panel A shows that Activin A increases SOX17 gene expression whileretinoic acid (RA) strongly suppresses SOX17 expression relative to theundifferentiated control media (SR20). Panel B shows the identicalpattern as well as a similar magnitude of these changes is reflected inSOX17⁺ cell number, indicating that Q-PCR measurement of SOX17 geneexpression is very reflective of changes at the single cell level.

FIG. 8A is a bar chart which shows that a culture of differentiatinghESCs in the presence of Activin A maintains a low level of AFP geneexpression while cells allowed to randomly differentiate in 10% fetalbovine serum (FBS) exhibit a strong upregulation of AFP. The differencein expression levels is approximately 7-fold.

FIGS. 8B-C are images of two micrographs showing that the suppression ofAFP expression by Activin A is also evident at the single cell level asindicated by the very rare and small clusters of AFP⁺ cells observed inActivin A treatment conditions (bottom) relative to 10% FBS alone (top).

FIGS. 9A-B are comparative images showing the quantitation of the AFP⁺cell number using flow cytometry. This figure demonstrates that themagnitude of change in AFP gene expression (FIG. 8A) in the presence(right panel) and absence (left panel) of Activin A exactly correspondsto the number of AFP⁺ cells, further supporting the utility of Q-PCRanalyses to indicate changes occurring at the individual cell level.

FIGS. 10A-F are micrographs which show that exposure of hESCs to nodal,Activin A and Activin B (NAA) yields a striking increase in the numberof SOX17⁺ cells over the period of 5 days (A-C). By comparing to therelative abundance of SOX17⁺ cells to the total number of cells presentin each field, as indicated by DAPI stained nuclei (D-F), it can be seenthat approximately 30-50% of all cells are immunoreactive for SOX17after five days treatment with NAA.

FIG. 11 is a bar chart which demonstrates that Activin A (0, 10, 30 or100 ng/mL) dose-dependently increases SOX17 gene expression indifferentiating hESCs. Increased expression is already robust after 3days of treatment on adherent cultures and continues through subsequent1, 3 and 5 days of suspension culture as well.

FIGS. 12A-C are bar charts which demonstrate the effect of Activin A onthe expression of MIXL1 (panel A), GATA4 (panel B) and HNF3b (panel C).Activin A dose-dependent increases are also observed for three othermarkers of definitive endoderm; MIXL1, GATA4 and HNF3b. The magnitudesof increased expression in response to activin dose are strikinglysimilar to those observed for SOX17, strongly indicating that Activin Ais specifying a population of cells that co-express all four genes(SOX17⁺, MIXL1⁺, GATA4⁺ and HNF3b⁺).

FIGS. 13A-C are bar charts which demonstrate the effect of Activin A onthe expression of AFP (panel A), SOX7 (panel B) and SPARC (panel C).There is an Activin A dose-dependent decrease in expression of thevisceral endoderm marker AFP. Markers of primitive endoderm (SOX7) andparietal endoderm (SPARC) remain either unchanged or exhibit suppressionat some time points indicating that Activin A does not act to specifythese extra-embryonic endoderm cell types. This further supports thefact that the increased expression of SOX17, MIXL1, GATA4, and HNF3b aredue to an increase in the number of definitive endoderm cells inresponse to Activin A.

FIGS. 14A-B are bar charts showing the effect of Activin A on ZIC1(panel A) and Brachyury expression (panel B) Consistent expression ofthe neural marker ZIC1 demonstrates that there is not a dose-dependenteffect of Activin A on neural differentiation. There is a notablesuppression of mesoderm differentiation mediated by 100 ng/mL of ActivinA treatment as indicated by the decreased expression of brachyury. Thisis likely the result of the increased specification of definitiveendoderm from the mesendoderm precursors. Lower levels of Activin Atreatment (10 and 30 ng/mL) maintain the expression of brachyury atlater time points of differentiation relative to untreated controlcultures.

FIGS. 15A-B are micrographs showing decreased parietal endodermdifferentiation in response to treatment with activins. Regions ofTM^(hi) parietal endoderm are found through the culture (A) whendifferentiated in serum alone, while differentiation to TM⁺ cells isscarce when activins are included (B) and overall intensity of TMimmunoreactivity is lower.

FIGS. 16A-D are micrographs which show marker expression in response totreatment with Activin A and Activin B. hESCs were treated for fourconsecutive days with Activin A and Activin B and triple labeled withSOX17, AFP and TM antibodies. Panel A—SOX17; Panel B—AFP; Panel C—TM;and Panel D—Phase/DAPI. Notice the numerous SOX17 positive cells (A)associated with the complete absence of AFP (B) and TM (C)immunoreactivity.

FIG. 17 is a micrograph showing the appearance of definitive endodermand visceral endoderm in vitro from hESCs. The regions of visceralendoderm are identified by AFP^(hi)/SOX17^(lo/−) while definitiveendoderm displays the complete opposite profile, SOX17^(hi)/AFP^(lo/−).This field was selectively chosen due to the proximity of these tworegions to each other. However, there are numerous times whenSOX17^(hi)/AFP^(lo/−) regions are observed in absolute isolation fromany regions of AFP^(hi) cells, suggesting the separate origination ofthe definitive endoderm cells from visceral endoderm cells.

FIG. 18 is a diagram depicting the TGFβ family of ligands and receptors.Factors activating AR Smads and BR Smads are useful in the production ofdefinitive endoderm from human embryonic stem cells (see, J CellPhysiol. 187:265-76).

FIG. 19 is a bar chart showing the induction of SOX17 expression overtime as a result of treatment with individual and combinations of TGFβfactors.

FIG. 20 is a bar chart showing the increase in SOX17⁺ cell number withtime as a result of treatment with combinations of TGFβ factors.

FIG. 21 is a bar chart showing induction of SOX17 expression over timeas a result of treatment with combinations of TGFβ factors.

FIG. 22 is a bar chart showing that Activin A induces a dose-dependentincrease in SOX17⁺ cell number.

FIG. 23 is a bar chart showing that addition of Wnt3a to Activin A andActivin B treated cultures increases SOX17 expression above the levelsinduced by Activin A and Activin B alone.

FIGS. 24A-C are bar charts showing differentiation to definitiveendoderm is enhanced in low FBS conditions. Treatment of hESCs withactivins A and B in media containing 2% FBS (2AA) yields a 2-3 timesgreater level of SOX17 expression as compared to the same treatment in10% FBS media (10AA) (panel A). Induction of the definitive endodermmarker MIXL1 (panel B) is also affected in the same way and thesuppression of AFP (visceral endoderm) (panel C) is greater in 2% FBSthan in 10% FBS conditions.

FIGS. 25A-D are micrographs which show SOX17⁺ cells are dividing inculture. SOX17 immunoreactive cells are present at the differentiatingedge of an hESC colony (C, D) and are labeled with proliferating cellnuclear antigen (PCNA) (panel B) yet are not co-labeled with OCT4 (panelC). In addition, clear mitotic figures can be seen by DAPI labeling ofnuclei in both SOX17⁺ cells (arrows) as well as OCT4⁺, undifferentiatedhESCs (arrowheads) (D).

FIG. 26 is a bar chart showing the relative expression level of CXCR4 indifferentiating hESCs under various media conditions.

FIGS. 27A-D are bar charts that show how a panel of definitive endodermmarkers share a very similar pattern of expression to CXCR4 across thesame differentiation treatments displayed in FIG. 26.

FIGS. 28A-E are bar charts showing how markers for mesoderm (BRACHYURY,MOX1), ectoderm (SOX1, ZIC1) and visceral endoderm (SOX7) exhibit aninverse relationship to CXCR4 expression across the same treatmentsdisplayed in FIG. 26.

FIGS. 29A-F are micrographs that show the relative difference in SOX17immunoreactive cells across three of the media conditions displayed inFIGS. 26-28.

FIGS. 30A-C are flow cytometry dot plots that demonstrate the increasein CXCR4⁺ cell number with increasing concentration of activin A addedto the differentiation media.

FIGS. 31A-D are bar charts that show the CXCR4⁺ cells isolated from thehigh dose activin A treatment (A100-CX+) are even further enriched fordefinitive endoderm markers than the parent population (A100).

FIG. 32 is a bar chart showing gene expression from CXCR4⁺ and CXCR4⁻cells isolated using fluorescence-activated cell sorting (FACS) as wellas gene expression in the parent populations. This demonstrates that theCXCR4⁺ cells contain essentially all the CXCR4 gene expression presentin each parent population and the CXCR4⁻ populations contain very littleor no CXCR4 gene expression.

FIGS. 33A-D are bar charts that demonstrate the depletion of mesoderm(BRACHYURY, MOX1), ectoderm (ZIC1) and visceral endoderm (SOX7) geneexpression in the CXCR4+ cells isolated from the high dose activin Atreatment which is already suppressed in expression of thesenon-definitive endoderm markers.

FIGS. 34A-M are bar charts showing the expression patterns of markergenes that can be used to identify definitive endoderm cells. Theexpression analysis of definitive endoderm markers, FGF17, VWF, CALCR,FOXQ1, CMKOR1 and CRIP1 is shown in panels G-L, respectively. Theexpression analysis of previously described lineage marking genes,SOX17, SOX7, SOX17/SOX7, TM, ZIC1, and MOX1 is shown in panels A-F,respectively. Panel M shows the expression analysis of CXCR4. Withrespect to each of panels A-M, the column labeled hESC indicates geneexpression from purified human embryonic stem cells; 2NF indicates cellstreated with 2% FBS, no activin addition; 0.1A100 indicates cellstreated with 0.1% FBS, 100 ng/ml Activin A; 1A100 indicates cellstreated with 1% FBS, 100 ng/ml Activin A; and 2A100 indicates cellstreated with 2% FBS, 100 ng/ml Activin A.

DETAILED DESCRIPTION

A crucial stage in early human development termed gastrulation occurs2-3 weeks after fertilization. Gastrulation is extremely significantbecause it is at this time that the three primary germ layers are firstspecified and organized (Lu et al., 2001; Schoenwolf and Smith, 2000).The ectoderm is responsible for the eventual formation of the outercoverings of the body and the entire nervous system whereas the heart,blood, bone, skeletal muscle and other connective tissues are derivedfrom the mesoderm. Definitive endoderm is defined as the germ layer thatis responsible for formation of the entire gut tube which includes theesophagus, stomach and small and large intestines, and the organs whichderive from the gut tube such as the lungs, liver, thymus, parathyroidand thyroid glands, gall bladder and pancreas (Grapin-Botton and Melton,2000; Kimelman and Griffin, 2000; Tremblay et al., 2000; Wells andMelton, 1999; Wells and Melton, 2000). A very important distinctionshould be made between the definitive endoderm and the completelyseparate lineage of cells termed primitive endoderm. The primitiveendoderm is primarily responsible for formation of extra-embryonictissues, mainly the parietal and visceral endoderm portions of theplacental yolk sac and the extracellular matrix material of Reichert'smembrane.

During gastrulation, the process of definitive endoderm formation beginswith a cellular migration event in which mesendoderm cells (cellscompetent to form mesoderm or endoderm) migrate through a structurecalled the primitive streak. Definitive endoderm is derived from cells,which migrate through the anterior portion of the streak and through thenode (a specialized structure at the anterior-most region of thestreak). As migration occurs, definitive endoderm populates first themost anterior gut tube and culminates with the formation of theposterior end of the gut tube.

In vivo analyses of the formation of definitive endoderm, such as thestudies in Zebrafish and Xenopus by Conlon et al., 1994; Feldman et al.,1998; Zhou et al., 1993; Aoki et al., 2002; Dougan et al., 2003;Tremblay et al., 2000; Vincent et al., 2003; Alexander et al., 1999;Alexander and Stainier, 1999; Kikuchi et al., 2001; Hudson et al., 1997and in mouse by Kanai-Azuma et al., 2002 lay a foundation for how onemight attempt to approach the development of a specific germ layer celltype in the culture dish using human embryonic stem cells. There are twoaspects associated with in vitro ESC culture that pose major obstaclesin the attempt to recapitulate development in the culture dish. First,organized germ layer or organ structures are not produced. The majorityof germ layer and organ specific genetic markers will be expressed in aheterogeneous fashion in the differentiating hESC culture system.Therefore it is difficult to evaluate formation of a specific tissue orcell type due to this lack of organ specific boundaries. Almost allgenes expressed in one cell type within a particular germ layer ortissue type are expressed in other cells of different germ layer ortissue types as well. Without specific boundaries there is considerablyless means to assign gene expression specificity with a small sample of1-3 genes. Therefore one must examine considerably more genes, some ofwhich should be present as well as some that should not be expressed inthe particular cell type of the organ or tissue of interest. Second, thetiming of gene expression patterns is crucial to movement down aspecific developmental pathway.

To further complicate matters, it should be noted that stem celldifferentiation in vitro is rather asynchronous, likely considerablymore so than in vivo. As such, one group of cells may be expressinggenes associated with gastrulation, while another group may be startingfinal differentiation. Furthermore, manipulation of hESC monolayers orembryoid bodies (EBs) with or without exogenous factor application mayresult in profound differences with respect to overall gene expressionpattern and state of differentiation. For these reasons, the applicationof exogenous factors must be timed according to gene expression patternswithin a heterogeneous cell mixture in order to efficiently move theculture down a specific differentiation pathway. It is also beneficialto consider the morphological association of the cells in the culturevessel. The ability to uniformly influence hESCs when formed into socalled embryoid bodies may be less optimal than hESCs grown anddifferentiated as monolayers and or hESC colonies in the culture vessel.

As an effective way to deal with the above-mentioned problems ofheterogeneity and asynchrony, some embodiments of the present inventioncontemplate combining a method for differentiating cells with a methodfor the enrichment, isolation and/or purification of intermediate celltypes in the differentiation pathway.

Embodiments of the present invention relate to novel, defined processesfor the production of definitive endoderm cells in culture bydifferentiating pluripotent cells, such as stem cells into multipotentdefinitive endoderm cells. As used herein, “multipotent” or “multipotentcell” refers to a cell type that can give rise to a limited number ofother particular cell types. As described above, definitive endodermcells do not differentiate into tissues produced from ectoderm ormesoderm, but rather, differentiate into the gut tube as well as organsthat are derived from the gut tube. In certain preferred embodiments,the definitive endoderm cells are derived from hESCs. Such processes canprovide the basis for efficient production of human endodermal derivedtissues such as pancreas, liver, lung, stomach, intestine and thyroid.For example, production of definitive endoderm may be the first step indifferentiation of a stem cell to a functional insulin-producing β-cell.To obtain useful quantities of insulin-producing β-cells, highefficiency of differentiation is desirable for each of thedifferentiation steps that occur prior to reaching the pancreaticislet/β-cell fate. Since differentiation of stem cells to definitiveendoderm cells represents perhaps the earliest step towards theproduction of functional pancreatic islet/fβ-cells (as shown in FIG. 1),high efficiency of differentiation at this step is particularlydesirable.

In view of the desirability of efficient differentiation of pluripotentcells to definitive endoderm cells, some aspects of the presentinvention relate to in vitro methodology that results in approximately50-80% conversion of pluripotent cells to definitive endoderm cells.Typically, such methods encompass the application of culture and growthfactor conditions in a defined and temporally specified fashion. Furtherenrichment of the cell population for definitive endoderm cells can beachieved by isolation and/or purification of the definitive endodermcells from other cells in the population by using a reagent thatspecifically binds to definitive endoderm cells. As such, aspects of thepresent invention relate to definitive endoderm cells as well as methodsfor producing and isolating and/or purifying such cells.

In order to determine the amount of definitive endoderm cells in a cellculture or cell population, a method of distinguishing this cell typefrom the other cells in the culture or in the population is desirable.Accordingly, certain embodiments of the present invention relate to cellmarkers whose presence, absence and/or relative expression levels arespecific for definitive endoderm and methods for detecting anddetermining the expression of such markers. As used herein, “expression”refers to the production of a material or substance as well as the levelor amount of production of a material or substance. Thus, determiningthe expression of a specific marker refers to detecting either therelative or absolute amount of the marker that is expressed or simplydetecting the presence or absence of the marker. As used herein,“marker” refers to any molecule that can be observed or detected. Forexample, a marker can include, but is not limited to, a nucleic acid,such as a transcript of a specific gene, a polypeptide product of agene, a non-gene product polypeptide, a glycoprotein, a carbohydrate, aglycolipd, a lipid, a lipoprotein or a small molecule.

In some embodiments of the present invention, the presence, absenceand/or level of expression of a marker is determined by quantitative PCR(Q-PCR). For example, the amount of transcript produced by certaingenetic markers, such as SOX17, CXCR4, OCT4, AFP, TM, SPARC, SOX7,MIXL1, GATA4, HNF3b, GSC, FGF17, VWF, CALCR, FOXQ1, CMKOR1, CRIP1 andother markers described herein is determined by quantitative Q-PCR. Inother embodiments, immunohistochemistry is used to detect the proteinsexpressed by the above-mentioned genes. In still other embodiments,Q-PCR and immunohistochemical techniques are both used to identify anddetermine the amount or relative proportions of such markers.

By using methods, such as those described above, to determine theexpression of one or more appropriate markers, it is possible toidentify definitive endoderm cells, as well as determine the proportionof definitive endoderm cells in a cell culture or cell population. Forexample, in some embodiments of the present invention, the definitiveendoderm cells or cell populations that are produced express the SOX17and/or the CXCR4 gene at a level of about 2 orders of magnitude greaterthan non-definitive endoderm cell types or cell populations. In otherembodiments, the definitive endoderm cells or cell populations that areproduced express the SOX17 and/or the CXCR4 gene at a level of more than2 orders of magnitude greater than non-definitive endoderm cell types orcell populations. In still other embodiments, the definitive endodermcells or cell populations that are produced express one or more of themarkers selected from the group consisting of SOX17, CXCR4, GSC, FGF17,VWF, CALCR, FOXQ1, CMKOR1 and CRIP1 at a level of about 2 or more than 2orders of magnitude greater than non-definitive endoderm cell types orcell populations.

Further aspects of the present invention relate to cell culturescomprising definitive endoderm as well as cell populations enriched indefinitive endoderm cells. As such, certain embodiments relate to cellcultures which comprise definitive endoderm cells, wherein at leastabout 50-80% of the cells in culture are definitive endoderm cells. Apreferred embodiment relates to cells cultures comprising human cells,wherein at least about 50-80% of the human cells in culture aredefinitive endoderm cells. Because the efficiency of the differentiationprocedure can be adjusted by modifying certain parameters, which includebut are not limited to, cell growth conditions, growth factorconcentrations and the timing of culture steps, the differentiationprocedures described herein can result in about 5%, about 10%, about15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%,about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about80%, about 85%, about 90%, about 95%, or greater than about 95%conversion of pluripotent cells to definitive endoderm. In otherembodiments of the present invention, conversion of a pluripotent cellpopulation, such as a stem cell population, to substantially puredefinitive endoderm cell population is contemplated.

The compositions and methods described herein have several usefulfeatures. For example, the cell cultures and cell populations comprisingdefinitive endoderm as well as the methods for producing such cellcultures and cell populations are useful for modeling the early stagesof human development. Furthermore, the compositions and methodsdescribed herein can also serve for therapeutic intervention in diseasestates, such as diabetes mellitus. For example, since definitiveendoderm serves as the source for only a limited number of tissues, itcan be used in the development of pure tissue or cell types.

Production of Definitive Endoderm from Pluripotent Cells

The definitive endoderm cell cultures and compositions comprisingdefinitive endoderm cells that are described herein can be produced frompluripotent cells, such as embryonic stem cells. As used herein,“embryonic” refers to a range of developmental stages of an organismbeginning with a single zygote and ending with a multicellular structurethat no longer comprises pluripotent or totipotent cells other thandeveloped gametic cells. In addition to embryos derived by gametefusion, the term “embryonic” refers to embryos derived by somatic cellnuclear transfer. A preferred method for deriving definitive endodermcells utilizes human embryonic stem cells (hESC) as the startingmaterial for definitive endoderm production. The embryonic stem cellsused in this method can be cells that originate from the morula,embryonic inner cell mass or those obtained from embryonic gonadalridges. Human stem cells can be maintained in culture in a pluripotentstate without substantial differentiation using methods that are knownin the art. Such methods are described, for example, in U.S. Pat. Nos.5,453,357, 5,670,372, 5,690,926 5,843,780, 6,200,806 and 6,251,671 thedisclosures of which are incorporated herein by reference in theirentireties.

In some embodiments of the methods described herein, hESCs aremaintained on a feeder layer. In such embodiments, any feeder layerwhich allows hESCs to be maintained in a pluripotent state can be usedin the methods described herein. One commonly used feeder layer for thecultivation of human embryonic stem cells is a layer of mousefibroblasts. More recently, human fibroblast feeder layers have beendeveloped for use in the cultivation of hESCs (see US Patent ApplicationNo. 2002/0072117, the disclosure of which is incorporated herein byreference in its entirety). Alternative embodiments of the methodsdescribed herein permit the maintenance of pluripotent hESC without theuse of a feeder layer. Such methods have been described in US PatentApplication No. 2003/0175956, the disclosure of which is incorporatedherein by reference in its entirety.

The human embryonic stem cells used herein can be maintained in cultureeither with or without serum. In some embodiments, serum replacement isused. In other embodiments, serum free culture techniques, such as thosedescribed in US Patent Application No. 2003/0190748, the disclosure ofwhich is incorporated herein by reference in its entirety, are used.

Stem cells are maintained in culture in a pluripotent state by routinepassage until it is desired that they be differentiated into definitiveendoderm. In some embodiments, differentiation to definitive endoderm isachieved by providing to the stem cell culture a growth factor of theTGFβ superfamily in an amount sufficient to promote differentiation todefinitive endoderm. Growth factors of the TGFβ superfamily which areuseful for the production of definitive endoderm are selected from theNodal/Activin or BMP subgroups. In some embodiments of thedifferentiation methods described herein, the growth factor is selectedfrom the group consisting of Nodal, Activin A, Activin B and BMP4.Additionally, the growth factor Wnt3a and other Wnt family members areuseful for the production of definitive endoderm cells. In certainembodiments of the present invention, combinations of any of theabove-mentioned growth factors can be used.

With respect to some of the embodiments of differentiation methodsdescribed herein, the above-mentioned growth factors are provided to thecells so that the growth factors are present in the cultures atconcentrations sufficient to promote differentiation of at least aportion of the stem cells to definitive endoderm. In some embodiments ofthe present invention, the above-mentioned growth factors are present inthe cell culture at a concentration of at least about 5 ng/ml, at leastabout 10 ng/ml, at least about 25 ng/ml, at least about 50 ng/ml, atleast about 75 ng/ml, at least about 100 ng/ml, at least about 200ng/ml, at least about 300 ng/ml, at least about 400 ng/ml, at leastabout 500 ng/ml, at least about 1000 ng/ml, at least about 2000 ng/ml,at least about 3000 ng/ml, at least about 4000 ng/ml, at least about5000 ng/ml or more than about 5000 ng/ml.

In certain embodiments of the present invention, the above-mentionedgrowth factors are removed from the cell culture subsequent to theiraddition. For example, the growth factors can be removed within aboutone day, about two days, about three days, about four days, about fivedays, about six days, about seven days, about eight days, about ninedays or about ten days after their addition. In a preferred embodiment,the growth factors are removed about four days after their addition.

Cultures of definitive endoderm cells can be grown in medium containingreduced serum or no serum. In certain embodiments of the presentinvention, serum concentrations can range from about 0.05% v/v to about20% v/v. For example, in certain embodiments, the serum concentration ofthe medium can be less than about 0.05% (v/v), less than about 0.1%(v/v), less than about 0.2% (v/v), less than about 0.3% (v/v), less thanabout 0.4% (v/v), less than about 0.5% (v/v), less than about 0.6%(v/v), less than about 0.7% (v/v), less than about 0.8% (v/v), less thanabout 0.9% (v/v), less than about 1% (v/v), less than about 2% (v/v),less than about 3% (v/v), less than about 4% (v/v), less than about 5%(v/v), less than about 6% (v/v), less than about 7% (v/v), less thanabout 8% (v/v), less than about 9% (v/v), less than about 10% (v/v),less than about 15% (v/v) or less than about 20% (v/v). In someembodiments, definitive endoderm cells are grown without serum. In otherembodiments, definitive endoderm cells are grown with serum replacement.In still other embodiments, definitive endoderm cells are grown in thepresence of B27. In such embodiments, the concentration of B27supplement can range from about 0.2% v/v to about 20% v/v.

The progression of the hESC culture to definitive endoderm can bemonitored by determining the expression of markers characteristic ofdefinitive endoderm. In some embodiments, the expression of certainmarkers are determined by detecting the presence or absence of themarker. Alternatively, the expression of certain markers can determinedby measuring the level at which the marker is present in the cells ofthe cell culture or cell population. In such embodiments, themeasurement of marker expression can be qualitative or quantitative. Onemethod of quantitating the expression markers that are produced bymarker genes is through the use of quantitative PCR (Q-PCR). Methods ofperforming Q-PCR are well known in the art. Other methods which areknown in the art can also be used to quantitate marker gene expression.For example, the expression of a marker gene product can be detected byusing antibodies specific for the marker gene product of interest. Insome embodiments of the present invention, the expression of markergenes characteristic of definitive endoderm as well as the lack ofsignificant expression of marker genes characteristic of hESCs and othercell types is determined

As described further in the Examples below, a reliable marker ofdefinitive endoderm is the SOX17 gene. As such, the definitive endodermcells produced by the methods described herein express the SOX17 markergene, thereby producing the SOX17 gene product. Other markers ofdefinitive endoderm are MIXL1, GATA4, HNF3b, GSC, FGF17, VWF, CALCR,FOXQ1, CMKOR1 and CRIP1. In some embodiments of the present invention,definitive endoderm cells express the SOX17 marker gene at a levelhigher than that of the SOX7 marker gene, which is characteristic ofprimitive and visceral endoderm (see Table 1). Additionally, in someembodiments, expression of the SOX17 marker gene is higher than theexpression of the OCT4 marker gene, which is characteristic of hESCs. Inother embodiments of the present invention, definitive endoderm cellsexpress the SOX17 marker gene at a level higher than that of the AFP,SPARC or Thrombomodulin (TM) marker genes. In certain embodiments of thepresent invention, the SOX17-expressing definitive endoderm cellsproduced by the methods described herein do not express significantlevels or amounts of PDX1 (PDX1-negative).

Another marker of definitive endoderm is the CXCR4 gene. The CXCR4 geneencodes a cell surface chemokine receptor whose ligand is thechemoattractant SDF-1. The principal roles of the CXCR4 receptor-bearingcells in the adult are believed to be the migration of hematopoeticcells to the bone marrow, lymphocyte trafficking and the differentiationof various B cell and macrophage blood cell lineages [Kim, C., andBroxmeyer, H. J. Leukocyte Biol. 65, 6-15 (1999)]. The CXCR4 receptoralso functions as a coreceptor for the entry of HIV-1 into T-cells[Feng, Y., et al. Science, 272, 872-877 (1996)]. In an extensive seriesof studies carried out by [McGrath, K. E. et al. Dev. Biology 213,442-456 (1999)], the expression of the chemokine receptor CXCR4 and itsunique ligand, SDF-1 [Kim, C., and Broxmyer, H., J. Leukocyte Biol. 65,6-15 (1999)], were delineated during early development and adult life inthe mouse. The CXCR4/SDF1 interaction in development became apparentwhen it was demonstrated that if either gene was disrupted in transgenicmice [Nagasawa et al. Nature, 382, 635-638 (1996)], Ma, Q., et alImmunity, 10, 463-471 (1999)] it resulted in late embryonic lethality.McGrath et al. demonstrated that CXCR4 is the most abundant chemokinereceptor messenger RNA detected during early gastrulating embryos (E7.5)using a combination of RNase protection and in situ hybridizationmethodologies. In the gastrulating embryo, CXCR4/SDF-1 signaling appearsto be mainly involved in inducing migration of primitive-streakgermlayer cells and is expressed on definitive endoderm, mesoderm andextraembryonic mesoderm present at this time. In E7.2-7.8 mouse embryos,CXCR4 and alpha-fetoprotein are mutually exclusive indicating a lack ofexpression in visceral endoderm [McGrath, K. E. et al. Dev. Biology 213,442-456 (1999)].

In some embodiments of the present invention, the definitive endodermcells produced by the methods described herein express the CXCR4 markergene. In other embodiments, the definitive endoderm cells produced bythe methods described herein express the CXCR4 marker gene as well asother markers of definitive endoderm including, but not limited to,SOX17, MIXL1, GATA4, HNF3b, GSC, FGF17, VWF, CALCR, FOXQ1, CMKOR1 andCRIP1. In some embodiments of the present invention, definitive endodermcells express the CXCR4 marker gene at a level higher than that of theSOX7 marker gene. Additionally, in some embodiments, expression of theCXCR4 marker gene is higher than the expression of the OCT4 marker gene.In other embodiments of the present invention, definitive endoderm cellsexpress the CXCR4 marker gene at a level higher than that of the AFP,SPARC or Thrombomodulin (TM) marker genes. In certain embodiments of thepresent invention, the CXCR4-expressing definitive endoderm cellsproduced by the methods described herein do not express significantlevels or amounts of PDX1 (PDX1-negative).

It will be appreciated that expression of CXCR4 in endodermal cells doesnot preclude the expression of SOX17. Accordingly, in some embodimentsof the present invention, definitive endoderm cells are those thatexpress both the SOX17 and CXCR4 marker genes at a level higher thanthat of the SOX7 marker gene. Additionally, in some embodiments, theexpression of both the SOX17 and CXCR4 marker genes is higher than theexpression of the OCT4 marker gene. In other embodiments of the presentinvention, definitive endoderm cells express both the SOX17 and theCXCR4 marker genes at a level higher than that of the AFP, SPARC orThrombomodulin (TM) marker genes. In certain embodiments of the presentinvention, the SOX17/CXCR4-expressing definitive endoderm cells producedby the methods described herein do not express significant levels oramounts of PDX1 (PDX1-negative).

It will be appreciated that SOX17 and/or CXCR4 marker expression isinduced over a range of different levels in definitive endoderm cellsdepending on the differentiation conditions. As such, in someembodiments of the present invention, the expression of the SOX17 markerand/or the CXCR4 marker in definitive endoderm cells or cell populationsis at least about 2-fold higher to at least about 10,000-fold higherthan the expression of the SOX17 marker and/or the CXCR4 marker innon-definitive endoderm cells or cell populations, for examplepluripotent stem cells. In other embodiments of the present invention,the expression of the SOX17 marker and/or the CXCR4 marker in definitiveendoderm cells or cell populations is at least about 4-fold higher, atleast about 6-fold higher, at least about 8-fold higher, at least about10-fold higher, at least about 15-fold higher, at least about 20-foldhigher, at least about 40-fold higher, at least about 80-fold higher, atleast about 100-fold higher, at least about 150-fold higher, at leastabout 200-fold higher, at least about 500-fold higher, at least about750-fold higher, at least about 1000-fold higher, at least about2500-fold higher, at least about 5000-fold higher, at least about7500-fold higher or at least about 10,000-fold higher than theexpression of the SOX17 marker and/or the CXCR4 marker in non-definitiveendoderm cells or cell populations, for example pluripotent stem cells.In some embodiments, the expression of the SOX17 marker and/or CXCR4marker in definitive endoderm cells or cell populations is infinitelyhigher than the expression of the SOX17 marker and/or the CXCR4 markerin non-definitive endoderm cells or cell populations, for examplepluripotent stem cells.

It will be appreciated that in some embodiments of the presentinvention, the expression of markers selected from the group consistingof GATA4, MIXL1, HNF3b, GSC, FGF17, VWF, CALCR, FOXQ1, CMKOR1 and CRIP1in definitive endoderm cells or cell populations is increased ascompared to the expression of GATA4, MIXL1, HNF3b, GSC, FGF17, VWF,CALCR, FOXQ1, CMKOR1 and CRIP1 in non-definitive endoderm cells or cellpopulations.

It will also be appreciated that there is a range of differences betweenthe expression level of the SOX17 marker and the expression levels ofthe OCT4, SPARC, AFP, TM and/or SOX7 markers in definitive endodermcells. Similarly, there exists a range of differences between theexpression level of the CXCR4 marker and the expression levels of theOCT4, SPARC, AFP, TM and/or SOX7 markers in definitive endoderm cells.As such, in some embodiments of the present invention, the expression ofthe SOX17 marker or the CXCR4 marker is at least about 2-fold higher toat least about 10,000-fold higher than the expression of OCT4, SPARC,AFP, TM and/or SOX7 markers. In other embodiments of the presentinvention, the expression of the SOX17 marker or the CXCR4 marker is atleast about 4-fold higher, at least about 6-fold higher, at least about8-fold higher, at least about 10-fold higher, at least about 15-foldhigher, at least about 20-fold higher, at least about 40-fold higher, atleast about 80-fold higher, at least about 100-fold higher, at leastabout 150-fold higher, at least about 200-fold higher, at least about500-fold higher, at least about 750-fold higher, at least about1000-fold higher, at least about 2500-fold higher, at least about5000-fold higher, at least about 7500-fold higher or at least about10,000-fold higher than the expression of OCT4, SPARC, AFP, TM and/orSOX7 markers. In some embodiments, OCT4, SPARC, AFP, TM and/or SOX7markers are not significantly expressed in definitive endoderm cells.

It will be appreciated that in some embodiments of the presentinvention, the expression of markers selected from the group consistingof GATA4, MIXL1, HNF3b, GSC, FGF17, VWF, CALCR, FOXQ1, CMKOR1 and CRIP1in definitive endoderm cells is increased as compared to the expressionof OCT4, SPARC, AFP, TM and/or SOX7 in definitive endoderm cells.

Compositions Comprising Definitive Endoderm

Some aspects of the present invention relate to compositions, such ascell populations and cell cultures, that comprise both pluripotentcells, such as stem cells, and definitive endoderm cells. For example,using the methods described herein, compositions comprising mixtures ofhESCs and definitive endoderm cells can be produced. In someembodiments, compositions comprising at least about 5 definitiveendoderm cells for about every 95 pluripotent cells are produced. Inother embodiments, compositions comprising at least about 95 definitiveendoderm cells for about every 5 pluripotent cells are produced.Additionally, compositions comprising other ratios of definitiveendoderm cells to pluripotent cells are contemplated. For example,compositions comprising at least about 1 definitive endoderm cell forabout every 1,000,000 pluripotent cells, at least about 1 definitiveendoderm cell for about every 100,000 pluripotent cells, at least about1 definitive endoderm cell for about every 10,000 pluripotent cells, atleast about 1 definitive endoderm cell for about every 1000 pluripotentcells, at least about 1 definitive endoderm cell for about every 500pluripotent cells, at least about 1 definitive endoderm cell for aboutevery 100 pluripotent cells, at least about 1 definitive endoderm cellfor about every 10 pluripotent cells, at least about 1 definitiveendoderm cell for about every 5 pluripotent cells, at least about 1definitive endoderm cell for about every 2 pluripotent cells, at leastabout 2 definitive endoderm cells for about every 1 pluripotent cell, atleast about 5 definitive endoderm cells for about every 1 pluripotentcell, at least about 10 definitive endoderm cells for about every 1pluripotent cell, at least about 20 definitive endoderm cells for aboutevery 1 pluripotent cell, at least about 50 definitive endoderm cellsfor about every 1 pluripotent cell, at least about 100 definitiveendoderm cells for about every 1 pluripotent cell, at least about 1000definitive endoderm cells for about every 1 pluripotent cell, at leastabout 10,000 definitive endoderm cells for about every 1 pluripotentcell, at least about 100,000 definitive endoderm cells for about every 1pluripotent cell and at least about 1,000,000 definitive endoderm cellsfor about every 1 pluripotent cell are contemplated. In some embodimentsof the present invention, the pluripotent cells are human pluripotentstem cells. In certain embodiments the stem cells are derived from amorula, the inner cell mass of an embryo or the gonadal ridges of anembryo. In certain other embodiments, the pluripotent cells are derivedfrom the gondal or germ tissues of a multicellular structure that hasdeveloped past the embryonic stage.

Some aspects of the present invention relate to cell cultures or cellpopulations comprising from at least about 5% definitive endoderm cellsto at least about 95% definitive endoderm cells. In some embodiments thecell cultures or cell populations comprise mammalian cells. In preferredembodiments, the cell cultures or cell populations comprise human cells.For example, certain specific embodiments relate to cell culturescomprising human cells, wherein from at least about 5% to at least about95% of the human cells are definitive endoderm cells. Other embodimentsof the present invention relate to cell cultures comprising human cells,wherein at least about 5%, at least about 10%, at least about 15%, atleast about 20%, at least about 25%, at least about 30%, at least about35%, at least about 40%, at least about 45%, at least about 50%, atleast about 55%, at least about 60%, at least about 65%, at least about70%, at least about 75%, at least about 80%, at least about 85%, atleast about 90% or greater than 90% of the human cells are definitiveendoderm cells.

Further embodiments of the present invention relate to compositions,such as cell cultures or cell populations, comprising human cells, suchas human definitive endoderm cells, wherein the expression of either theSOX17 or the CXCR4 marker is greater than the expression of the OCT 4,SPARC, alpha-fetoprotein (AFP), Thrombomodulin (TM) and/or SOX7 markerin at least about 5% of the human cells. In other embodiments, theexpression of either the SOX17 or the CXCR4 marker is greater than theexpression of the OCT4, SPARC, AFP, TM and/or SOX7 marker in at leastabout 10% of the human cells, in at least about 15% of the human cells,in at least about 20% of the human cells, in at least about 25% of thehuman cells, in at least about 30% of the human cells, in at least about35% of the human cells, in at least about 40% of the human cells, in atleast about 45% of the human cells, in at least about 50% of the humancells, in at least about 55% of the human cells, in at least about 60%of the human cells, in at least about 65% of the human cells, in atleast about 70% of the human cells, in at least about 75% of the humancells, in at least about 80% of the human cells, in at least about 85%of the human cells, in at least about 90% of the human cells, in atleast about 95% of the human cells or in greater than 95% of the humancells.

It will be appreciated that some embodiments of the present inventionrelate to compositions, such as cell cultures or cell populations,comprising human cells, such as human definitive endoderm cells, whereinthe expression of one or more markers selected from the group consistingof GATA4, MIXL1, HNF3b, GSC, FGF17, VWF, CALCR, FOXQ1, CMKOR1 and CRIP1is greater than the expression of the OCT4, SPARC, AFP, TM and/or SOX7markers in from at least about 5% to greater than at least about 95% ofthe human cells.

Still other embodiments of the present invention relate to compositions,such as cell cultures or cell populations, comprising human cells, suchas human definitive endoderm cells, wherein the expression both theSOX17 and the CXCR4 marker is greater than the expression of the OCT4,SPARC, AFP, TM and/or SOX7 marker in at least about 5% of the humancells. In other embodiments, the expression of both the SOX17 and theCXCR4 marker is greater than the expression of the OCT4, SPARC, AFP, TMand/or SOX7 marker in at least about 10% of the human cells, in at leastabout 15% of the human cells, in at least about 20% of the human cells,in at least about 25% of the human cells, in at least about 30% of thehuman cells, in at least about 35% of the human cells, in at least about40% of the human cells, in at least about 45% of the human cells, in atleast about 50% of the human cells, in at least about 55% of the humancells, in at least about 60% of the human cells, in at least about 65%of the human cells, in at least about 70% of the human cells, in atleast about 75% of the human cells, in at least about 80% of the humancells, in at least about 85% of the human cells, in at least about 90%of the human cells, in at least about 95% of the human cells or ingreater than 95% of the human cells.

It will be appreciated that some embodiments of the present inventionrelate to compositions, such as cell cultures or cell populations,comprising human cells, such as human definitive endoderm cells, whereinthe expression of the GATA4, MIXL1, HNF3b, GSC, FGF17, VWF, CALCR,FOXQ1, CMKOR1 and CRIP1 markers is greater than the expression of theOCT4, SPARC, AFP, TM and/or SOX7 markers in from at least about 5% togreater than at least about 95% of the human cells.

Additional embodiments of the present invention relate to compositions,such as cell cultures or cell populations, comprising mammalianendodermal cells, such as human endoderm cells, wherein the expressionof either the SOX17 or the CXCR4 marker is greater than the expressionof the OCT4, SPARC, AFP, TM and/or SOX7 marker in at least about 5% ofthe endodermal cells. In other embodiments, the expression of either theSOX17 or the CXCR4 marker is greater than the expression of the OCT4,SPARC, AFP, TM and/or SOX7 marker in at least about 10% of theendodermal cells, in at least about 15% of the endodermal cells, in atleast about 20% of the endodermal cells, in at least about 25% of theendodermal cells, in at least about 30% of the endodermal cells, in atleast about 35% of the endodermal cells, in at least about 40% of theendodermal cells, in at least about 45% of the endodermal cells, in atleast about 50% of the endodermal cells, in at least about 55% of theendodermal cells, in at least about 60% of the endodermal cells, in atleast about 65% of the endodermal cells, in at least about 70% of theendodermal cells, in at least about 75% of the endodermal cells, in atleast about 80% of the endodermal cells, in at least about 85% of theendodermal cells, in at least about 90% of the endodermal cells, in atleast about 95% of the endodermal cells or in greater than 95% of theendodermal cells.

It will be appreciated that some embodiments of the present inventionrelate to compositions, such as cell cultures or cell populationscomprising mammalian endodermal cells, wherein the expression of one ormore markers selected from the group consisting of GATA4, MIXL1, HNF3b,GSC, FGF17, VWF, CALCR, FOXQ1, CMKOR1 and CRIP1 is greater than theexpression of the OCT4, SPARC, AFP, TM and/or SOX7 markers in from atleast about 5% to greater than at least about 95% of the endodermalcells.

Still other embodiments of the present invention relate to compositions,such as cell cultures or cell populations, comprising mammalianendodermal cells, such as human endodermal cells, wherein the expressionboth the SOX17 and the CXCR4 marker is greater than the expression ofthe OCT4, SPARC, AFP, TM and/or SOX7 marker in at least about 5% of theendodermal cells. In other embodiments, the expression of both the SOX17and the CXCR4 marker is greater than the expression of the OCT4, SPARC,AFP, TM and/or SOX7 marker in at least about 10% of the endodermalcells, in at least about 15% of the endodermal cells, in at least about20% of the endodermal cells, in at least about 25% of the endodermalcells, in at least about 30% of the endodermal cells, in at least about35% of the endodermal cells, in at least about 40% of the endodermalcells, in at least about 45% of the endodermal cells, in at least about50% of the endodermal cells, in at least about 55% of the endodermalcells, in at least about 60% of the endodermal cells, in at least about65% of the endodermal cells, in at least about 70% of the endodermalcells, in at least about 75% of the endodermal cells, in at least about80% of the endodermal cells, in at least about 85% of the endodermalcells, in at least about 90% of the endodermal cells, in at least about95% of the endodermal cells or in greater than 95% of the endodermalcells.

It will be appreciated that some embodiments of the present inventionrelate to compositions, such as cell cultures or cell populationscomprising mammalian endodermal cells, wherein the expression of theGATA4, MIXL1, HNF3b, GSC, FGF17, VWF, CALCR, FOXQ1, CMKOR1 and CRIP1markers is greater than the expression of the OCT4, SPARC, AFP, TMand/or SOX7 markers in from at least about 5% to greater than at leastabout 95% of the endodermal cells.

Using the methods described herein, compositions comprising definitiveendoderm cells substantially free of other cell types can be produced.With respect to cells in cell cultures or in cell populations, the term“substantially free of” means that the specified cell type of which thecell culture or cell population is free, is present in an amount of lessthan about 5% of the total number of cells present in the cell cultureor cell population. In some embodiments of the present invention, thedefinitive endoderm cell populations or cell cultures produced by themethods described herein are substantially free of cells thatsignificantly express the OCT4, SOX7, AFP, SPARC, TM, ZIC1 or BRACHmarker genes.

In one embodiment of the present invention, a description of adefinitive endoderm cell based on the expression of marker genes is,SOX17 high, MIXL1 high, AFP low, SPARC low, Thrombomodulin low, SOX7low, CXCR4 high.

Enrichment, Isolation and/or Purification of Definitive Endoderm

With respect to additional aspects of the present invention, definitiveendoderm cells can be enriched, isolated and/or purified by using anaffinity tag that is specific for such cells. Examples of affinity tagsspecific for definitive endoderm cells are antibodies, ligands or otherbinding agents that are specific to a marker molecule, such as apolypeptide, that is present on the cell surface of definitive endodermcells but which is not substantially present on other cell types thatwould be found in a cell culture produced by the methods describedherein. In some embodiments, an antibody which binds to CXCR4 is used asan affinity tag for the enrichment, isolation or purification ofdefinitive endoderm cells. In other embodiments, the chemokine SDF-1 orother molecules based on SDF-1 can also be used as affinity tags. Suchmolecules include, but not limited to, SDF-1 fragments, SDF-1 fusions orSDF-1 mimetics.

Methods for making antibodies and using them for cell isolation areknown in the art and such methods can be implemented for use with theantibodies and cells described herein. In one embodiment, an antibodywhich binds to CXCR4 is attached to a magnetic bead then allowed to bindto definitive endoderm cells in a cell culture which has beenenzymatically treated to reduce intercellular and substrate adhesion.The cell/antibody/bead complexes are then exposed to a movable magneticfield which is used to separate bead-bound definitive endoderm cellsfrom unbound cells. Once the definitive endoderm cells are physicallyseparated from other cells in culture, the antibody binding is disruptedand the cells are replated in appropriate tissue culture medium.

Embodiments of the present invention contemplate additional methods forobtaining enriched, isolated or purified definitive endoderm cellcultures or populations. For example, in some embodiments, the CXCR4antibody is incubated with definitive endoderm-containing cell culturethat has been treated to reduce intercellular and substrate adhesion.The cells are then washed, centrifuged and resuspended. The cellsuspension is then incubated with a secondary antibody, such as anFITC-conjugated antibody that is capable of binding to the primaryantibody. The cells are then washed, centrifuged and resuspended inbuffer. The cell suspension is then analyzed and sorted using afluorescence activated cell sorter (FACS). CXCR4-positive cells arecollected separately from CXCR4-negative cells, thereby resulting in theisolation of such cell types. If desired, the isolated cell compositionscan be further purified by using an alternate affinity-based method orby additional rounds of sorting using the same or different markers thatare specific for definitive endoderm.

In other embodiments of the present invention, definitive endoderm isenriched, isolated and/or purified using a ligand or other molecule thatbinds to CXCR4. In some embodiments, the molecule is SDF-1 or afragment, fusion or mimetic thereof.

In preferred embodiments, definitive endoderm cells are enriched,isolated and/or purified from other non-definitive endoderm cells afterthe stem cell cultures are induced to differentiate towards thedefinitive endoderm lineage. It will be appreciated that theabove-described enrichment, isolation and purification procedures can beused with such cultures at any stage of differentiation.

In addition to the procedures just described, definitive endoderm cellsmay also be isolated by other techniques for cell isolation.Additionally, definitive endoderm cells may also be enriched or isolatedby methods of serial subculture in growth conditions which promote theselective survival or selective expansion of said definitive endodermcells.

Using the methods described herein, enriched, isolated and/or purifiedpopulations of definitive endoderm cells and or tissues can be producedin vitro from pluripotent cell cultures or cell populations, such asstem cell cultures or populations, which have undergone at least somedifferentiation. In some embodiments, the cells undergo randomdifferentiation. In a preferred embodiment, however, the cells aredirected to differentiate primarily into definitive endoderm. Somepreferred enrichment, isolation and/or purification methods relate tothe in vitro production of definitive endoderm from human embryonic stemcells. Using the methods described herein, cell populations or cellcultures can be enriched in definitive endoderm content by at leastabout 2- to about 1000-fold as compared to untreated cell populations orcell cultures. In some embodiments, definitive endoderm cells can beenriched by at least about 5- to about 500-fold as compared to untreatedcell populations or cell cultures. In other embodiments, definitiveendoderm cells can be enriched from at least about 10- to about 200-foldas compared to untreated cell populations or cell cultures. In stillother embodiments, definitive endoderm cells can be enriched from atleast about 20- to about 100-fold as compared to untreated cellpopulations or cell cultures. In yet other embodiments, definitiveendoderm cells can be enriched from at least about 40- to about 80-foldas compared to untreated cell populations or cell cultures. In certainembodiments, definitive endoderm cells can be enriched from at leastabout 2- to about 20-fold as compared to untreated cell populations orcell cultures.

Having generally described this invention, a further understanding canbe obtained by reference to certain specific examples which are providedherein for purposes of illustration only, and are not intended to belimiting.

EXAMPLES

Many of the examples below describe the use of pluripotent human cells.Methods of producing pluripotent human cells are well known in the artand have been described numerous scientific publications, including U.S.Pat. Nos. 5,453,357, 5,670,372, 5,690,926, 6,090,622, 6,200,806 and6,251,671 as well as U.S. Patent Application Publication No.2004/0229350, the disclosures of which are incorporated herein byreference in their entireties.

Example 1 Human ES Cells

For our studies of endoderm development we employed human embryonic stemcells, which are pluripotent and can divide seemingly indefinitely inculture while maintaining a normal karyotype. ES cells were derived fromthe 5-day-old embryo inner cell mass using either immunological ormechanical methods for isolation. In particular, the human embryonicstem cell line hESCyt-25 was derived from a supernumerary frozen embryofrom an in vitro fertilization cycle following informed consent by thepatient. Upon thawing the hatched blastocyst was plated on mouseembryonic fibroblasts (MEF), in ES medium (DMEM, 20% FBS, non essentialamino acids, beta-mercaptoethanol, ITS supplement). The embryo adheredto the culture dish and after approximately two weeks, regions ofundifferentiated hESCs were transferred to new dishes with MEFs.Transfer was accomplished with mechanical cutting and a brief digestionwith dispase, followed by mechanical removal of the cell clusters,washing and re-plating. Since derivation, hESCyt-25 has been seriallypassaged over 100 times. We employed the hESCyt-25 human embryonic stemcell line as our starting material for the production of definitiveendoderm.

It will be appreciated by those of skill in the art that stem cells orother pluripotent cells can also be used as starting material for thedifferentiation procedures described herein. For example, cells obtainedfrom embryonic gonadal ridges, which can be isolated by methods known inthe art, can be used as pluripotent cellular starting material.

Example 2 hESCyt-25 Characterization

The human embryonic stem cell line, hESCyt-25 has maintained a normalmorphology, karyotype, growth and self-renewal properties over 18 monthsin culture. This cell line displays strong immunoreactivity for theOCT4, S SEA-4 and TRA-1-60 antigens, all of which, are characteristic ofundifferentiated hESCs and displays alkaline phosphatase activity aswell as a morphology identical to other established hESC lines.Furthermore, the human stem cell line, hESCyt-25, also readily formsembryoid bodies (EBs) when cultured in suspension. As a demonstration ofits pluripotent nature, hESCyT-25 differentiates into various cell typesthat represent the three principal germ layers. Ectoderm production wasdemonstrated by Q-PCR for ZIC1 as well as immunocytochemistry (ICC) fornestin and more mature neuronal markers. Immunocytochemical staining forβ-III tubulin was observed in clusters of elongated cells,characteristic of early neurons. Previously, we treated EBs insuspension with retinoic acid, to induce differentiation of pluripotentstem cells to visceral endoderm (VE), an extra-embryonic lineage.Treated cells expressed high levels of α-fetoprotein (AFP) and SOX7, twomarkers of VE, by 54 hours of treatment. Cells differentiated inmonolayer expressed AFP in sporadic patches as demonstrated byimmunocytochemical staining. As will be described below, the hESCyT-25cell line was also capable of forming definitive endoderm, as validatedby real-time quantitative polymerase chain reaction (Q-PCR) andimmunocytochemistry for SOX17, in the absence of AFP expression. Todemonstrate differentiation to mesoderm, differentiating EBs wereanalyzed for Brachyury gene expression at several time points. Brachyuryexpression increased progressively over the course of the experiment. Inview of the foregoing, the hESCyT-25 line is pluripotent as shown by theability to form cells representing the three germ layers.

Example 3 Production of SOX17 Antibody

A primary obstacle to the identification of definitive endoderm in hESCcultures is the lack of appropriate tools. We therefore undertook theproduction of an antibody raised against human SOX17 protein.

The marker SOX17 is expressed throughout the definitive endoderm as itforms during gastrulation and its expression is maintained in the guttube (although levels of expression vary along the A-P axis) untilaround the onset of organogenesis. SOX17 is also expressed in a subsetof extra-embryonic endoderm cells. No expression of this protein hasbeen observed in mesoderm or ectoderm. It has now been discovered thatSOX17 is an appropriate marker for the definitive endoderm lineage whenused in conjunction with markers to exclude extra-embryonic lineages.

As described in detail herein, the SOX17 antibody was utilized tospecifically examine effects of various treatments and differentiationprocedures aimed at the production of SOX17 positive definitive endodermcells. Other antibodies reactive to AFP, SPARC and Thrombomodulin werealso employed to rule out the production of visceral and parietalendoderm (extra-embryonic endoderm).

In order to produce an antibody against SOX17, a portion of the humanSOX17 cDNA (SEQ ID NO: 1) corresponding to amino acids 172-414 (SEQ IDNO: 2) in the carboxyterminal end of the SOX17 protein (FIG. 2) was usedfor genetic immunization in rats at the antibody production company,GENOVAC (Freiberg, Germany), according to procedures developed there.Procedures for genetic immunization can be found in U.S. Pat. Nos.5,830,876, 5,817,637, 6,165,993 and 6,261,281 as well as InternationalPatent Application Publication Nos. WO00/29442 and WO99/13915, thedisclosures of which are incorporated herein by reference in theirentireties.

Other suitable methods for genetic immunization are also described inthe non-patent literature. For example, Barry et al. describe theproduction of monoclonal antibodies by genetic immunization inBiotechniques 16: 616-620, 1994, the disclosure of which is incorporatedherein by reference in its entirety. Specific examples of geneticimmunization methods to produce antibodies against specific proteins canbe found, for example, in Costaglia et al., (1998) Genetic immunizationagainst the human thyrotropin receptor causes thyroiditis and allowsproduction of monoclonal antibodies recognizing the native receptor, J.Immunol. 160: 1458-1465; Kilpatrick et al (1998) Gene gun deliveredDNA-based immunizations mediate rapid production of murine monoclonalantibodies to the Flt-3 receptor, Hybridoma 17: 569-576; Schmolke etal., (1998) Identification of hepatitis G virus particles in human serumby E2-specific monoclonal antibodies generated by DNA immunization, J.Virol. 72: 4541-4545; Krasemann et al., (1999) Generation of monoclonalantibodies against proteins with an unconventional nucleic acid-basedimmunization strategy, J. Biotechnol. 73: 119-129; and Ulivieri et al.,(1996) Generation of a monoclonal antibody to a defined portion of theHeliobacter pylori vacuolating cytotoxin by DNA immunization, J.Biotechnol. 51: 191-194, the disclosures of which are incorporatedherein by reference in their entireties.

SOX7 and SOX18 are the closest Sox family relatives to SOX17 as depictedin the relational dendrogram shown in FIG. 3. We employed the human SOX7polypeptide as a negative control to demonstrate that the SOX17 antibodyis specific for SOX17 and does not react with its closest family member.In particular, to demonstrate that the antibody produced by geneticimmunization is specific for SOX17, SOX7 and other proteins wereexpressed in human fibroblasts, and then, analyzed for cross reactivitywith the SOX17 antibody by Western blot and ICC. For example, thefollowing methods were utilized for the production of the SOX17, SOX7and EGFP expression vectors, their transfection into human fibroblastsand analysis by Western blot. Expression vectors employed for theproduction of SOX17, SOX7, and EGFP were pCMV6 (OriGene Technologies,Inc., Rockville, Md.), pCMV-SPORT6 (Invitrogen, Carlsbad, Calif.) andpEGFP-N1 (Clonetech, Palo Alto, Calif.), respectively. For proteinproduction, telomerase immortalized MDX human fibroblasts weretransiently transfected with supercoiled DNA in the presence ofLipofectamine 2000 (Invitrogen, Carlsbad, Calif.). Total cellularlysates were collected 36 hours post-transfection in 50 mM TRIS-HCl (pH8), 150 mM NaCl, 0.1% SDS, 0.5% deoxycholate, containing a cocktail ofprotease inhibitors (Roche Diagnostics Corporation, Indianapolis, Ind.).Western blot analysis of 100 μg of cellular proteins, separated bySDS-PAGE on NuPAGE (4-12% gradient polyacrylamide, Invitrogen, Carlsbad,Calif.), and transferred by electro-blotting onto PDVF membranes(Hercules, Calif.), were probed with a 1/1000 dilution of the rat SOX17anti-serum in 10 mM TRIS-HCl (pH 8), 150 mM NaCl, 10% BSA, 0.05%Tween-20 (Sigma, St. Louis, Mo.), followed by Alkaline Phosphataseconjugated anti-rat IgG (Jackson ImmunoResearch Laboratories, WestGrove, Pa.), and revealed through Vector Black Alkaline Phosphatasestaining (Vector Laboratories, Burlingame, Calif.). The proteins sizestandard used was wide range color markers (Sigma, St. Louis, Mo.).

In FIG. 4, protein extracts made from human fibroblast cells that weretransiently transfected with SOX17, SOX7 or EGFP cDNA's were probed onWestern blots with the SOX17 antibody. Only the protein extract fromhSOX17 transfected cells produced a band of ˜51 Kda which closelymatched the predicted 46 Kda molecular weight of the human SOX17protein. There was no reactivity of the SOX17 antibody to extracts madefrom either human SOX7 or EGFP transfected cells. Furthermore, the SOX17antibody clearly labeled the nuclei of human fibroblast cellstransfected with the hSOX17 expression construct but did not label cellstransfected with EGFP alone. As such, the SOX17 antibody exhibitsspecificity by ICC.

Example 4 Validation of SOX17 Antibody as a Marker of DefinitiveEndoderm

As evidence that the SOX17 antibody is specific for human SOX17 proteinand furthermore marks definitive endoderm, partially differentiatedhESCs were co-labeled with SOX17 and AFP antibodies. It has beendemonstrated that SOX17, SOX7, which is a closely related member of theSOX gene family subgroup F (FIG. 3), and AFP are each expressed invisceral endoderm. However, AFP and SOX7 are not expressed in definitiveendoderm cells at levels detectable by ICC, and thus, they be canemployed as negative markers for bonifide definitive endoderm cells. Itwas shown that SOX17 antibody labels populations of cells that exist asdiscrete groupings of cells or are intermingled with AFP positive cells.In particular, FIG. 5A shows that small numbers of SOX17 cells wereco-labeled with AFP; however, regions were also found where there werelittle or no AFP⁺ cells in the field of SOX17⁺ cells (FIG. 5B).Similarly, since parietal endoderm has also been reported to expressSOX17, antibody co-labeling with SOX17 together with the parietalmarkers SPARC and/or Thrombomodulin (TM) can be used to identify theSOX17⁺ cells which are parietal endoderm. As shown in FIGS. 6A-C,Thrombomodulin and SOX17 co-labelled parietal endoderm cells wereproduced by random differentiation of hES cells.

In view of the above cell labelling experiments, the identity of adefinitive endoderm cell can be established by the marker profileSOX17^(hi)/AFP^(lo)/[TM^(lo) or SPARC^(lo)]. In other words, theexpression of the SOX17 marker is greater than the expression of the AFPmarker, which is characteristic of visceral endoderm, and the TM orSPARC markers, which are characteristic of parietal endoderm.Accordingly, those cells positive for SOX17 but negative for AFP andnegative for TM or SPARC are definitive endoderm.

As a further evidence of the specificity of theSOX17^(hi)/AFP^(lo)/TM^(lo)/SPARC^(lo) marker profile as predictive ofdefinitive endoderm, SOX17 and AFP gene expression was quantitativelycompared to the relative number of antibody labeled cells. As shown inFIG. 7A, hESCs treated with retinoic acid (visceral endoderm inducer),or Activin A (definitive endoderm inducer), resulted in a 10-folddifference in the level of SOX17 mRNA expression. This result mirroredthe 10-fold difference in SOX17 antibody-labeled cell number (FIG. 7B).Furthermore, as shown in FIG. 8A, Activin A treatment of hESCssuppressed AFP gene expression by 6.8-fold in comparison to notreatment. This was visually reflected by a dramatic decrease in thenumber of AFP labeled cells in these cultures as shown in FIGS. 8B-C. Toquantify this further, it was demonstrated that this approximately7-fold decrease in AFP gene expression was the result of a similar7-fold decrease in AFP antibody-labeled cell number as measured by flowcytometry (FIGS. 9A-B). This result is extremely significant in that itindicates that quantitative changes in gene expression as seen by Q-PCRmirror changes in cell type specification as observed by antibodystaining

Incubation of hESCs in the presence of Nodal family members (Nodal,Activin A and Activin B—NAA) resulted in a significant increase in SOX17antibody-labeled cells over time. By 5 days of continuous activintreatment greater than 50% of the cells were labeled with SOX17 (FIGS.10A-F). There were few or no cells labeled with AFP after 5 days ofactivin treatment.

In summary, the antibody produced against the carboxy-terminal 242 aminoacids of the human SOX17 protein identified human SOX17 protein onWestern blots but did not recognize SOX7, it's closest Sox familyrelative. The SOX17 antibody recognized a subset of cells indifferentiating hESC cultures that were primarily SOX17⁺/AFP^(lo/−)(greater than 95% of labeled cells) as well as a small percentage (<5%)of cells that co-label for SOX17 and AFP (visceral endoderm). Treatmentof hESC cultures with activins resulted in a marked elevation of SOX17gene expression as well as SOX17 labeled cells and dramaticallysuppressed the expression of AFP mRNA and the number of cells labeledwith AFP antibody.

Example 5 Q-PCR Gene Expression Assay

In the following experiments, real-time quantitative RT-PCR (Q-PCR) wasthe primary assay used for screening the effects of various treatmentson hESC differentiation. In particular, real-time measurements of geneexpression were analyzed for multiple marker genes at multiple timepoints by Q-PCR. Marker genes characteristic of the desired as well asundesired cell types were evaluated to gain a better understanding ofthe overall dynamics of the cellular populations. The strength of Q-PCRanalysis includes its extreme sensitivity and relative ease ofdeveloping the necessary markers, as the genome sequence is readilyavailable. Furthermore, the extremely high sensitivity of Q-PCR permitsdetection of gene expression from a relatively small number of cellswithin a much larger population. In addition, the ability to detect verylow levels of gene expression provides indications for “differentiationbias” within the population. The bias towards a particulardifferentiation pathway, prior to the overt differentiation of thosecellular phenotypes, is unrecognizable using immunocytochemicaltechniques. For this reason, Q-PCR provides a method of analysis that isat least complementary and potentially much superior toimmunocytochemical techniques for screening the success ofdifferentiation treatments. Additionally, Q-PCR provides a mechanism bywhich to evaluate the success of a differentiation protocol in aquantitative format at semi-high throughput scales of analysis.

The approach taken here was to perform relative quantitation using SYBRGreen chemistry on a Rotor Gene 3000 instrument (Corbett Research) and atwo-step RT-PCR format. Such an approach allowed for the banking of cDNAsamples for analysis of additional marker genes in the future, thusavoiding variability in the reverse transcription efficiency betweensamples.

Primers were designed to lie over exon-exon boundaries or span intronsof at least 800 by when possible, as this has been empiricallydetermined to eliminate amplification from contaminating genomic DNA.When marker genes were employed that do not contain introns or theypossess pseudogenes, DNase I treatment of RNA samples was performed.

We routinely used Q-PCR to measure the gene expression of multiplemarkers of target and non-target cell types in order to provide a broadprofile description of gene expression in cell samples. The markersrelevant for the early phases of hESC differentiation (specificallyectoderm, mesoderm, definitive endoderm and extra-embryonic endoderm)and for which validated primer sets are available are provided below inTable 1. The human specificity of these primer sets has also beendemonstrated. This is an important fact since the hESCs were often grownon mouse feeder layers. Most typically, triplicate samples were takenfor each condition and independently analyzed in duplicate to assess thebiological variability associated with each quantitative determination.

To generate PCR template, total RNA was isolated using RNeasy (Qiagen)and quantitated using RiboGreen (Molecular Probes). Reversetranscription from 350-500 ng of total RNA was carried out using theiScript reverse transcriptase kit (BioRad), which contains a mix ofoligo-dT and random primers. Each 20 μL reaction was subsequentlydiluted up to 100 μL total volume and 3 μL was used in each 10 μL Q-PCRreaction containing 400 nM forward and reverse primers and 5 μL 2×SYBRGreen master mix (Qiagen). Two step cycling parameters were usedemploying a 5 second denature at 85-94° C. (specifically selectedaccording to the melting temp of the amplicon for each primer set)followed by a 45 second anneal/extend at 60° C. Fluorescence data wascollected during the last 15 seconds of each extension phase. A threepoint, 10-fold dilution series was used to generate the standard curvefor each run and cycle thresholds (Ct's) were converted to quantitativevalues based on this standard curve. The quantitated values for eachsample were normalized to housekeeping gene performance and then averageand standard deviations were calculated for triplicate samples. At theconclusion of PCR cycling, a melt curve analysis was performed toascertain the specificity of the reaction. A single specific product wasindicated by a single peak at the T_(m) appropriate for that PCRamplicon. In addition, reactions performed without reverse transcriptaseserved as the negative control and do not amplify.

A first step in establishing the Q-PCR methodology was validation ofappropriate housekeeping genes (HGs) in the experimental system. Sincethe HG was used to normalize across samples for the RNA input, RNAintegrity and RT efficiency, it was of value that the HG exhibited aconstant level of expression over time in all sample types in order forthe normalization to be meaningful. We measured the expression levels ofCyclophilin G, hypoxanthine phosphoribosyltransferase 1 (HPRT),beta-2-microglobulin, hydroxymethylbiane synthase (HMBS), TATA-bindingprotein (TBP), and glucoronidase beta (GUS) in differentiating hESCs.Our results indicated that beta-2-microglobulin expression levelsincreased over the course of differentiation and therefore we excludedthe use of this gene for normalization. The other genes exhibitedconsistent expression levels over time as well as across treatments. Weroutinely used both Cyclophilin G and GUS to calculate a normalizationfactor for all samples. The use of multiple HGs simultaneously reducesthe variability inherent to the normalization process and increases thereliability of the relative gene expression values.

After obtaining genes for use in normalization, Q-PCR was then utilizedto determine the relative gene expression levels of many marker genesacross samples receiving different experimental treatments. The markergenes employed have been chosen because they exhibit enrichment inspecific populations representative of the early germ layers and inparticular have focused on sets of genes that are differentiallyexpressed in definitive endoderm and extra-embryonic endoderm. Thesegenes as well as their relative enrichment profiles are highlighted inTable 1.

TABLE 1 Germ Layer Gene Expression Domains Endoderm SOX17 definitive,visceral and parietal endoderm MIXL1 endoderm and mesoderm GATA4definitive and primitive endoderm HNF3b definitive endoderm andprimitive endoderm, mesoderm, neural plate GSC endoderm and mesodermExtra-embryonic SOX7 visceral endoderm AFP visceral endoderm, liverSPARC parietal endoderm TM parietal endoderm/trophectoderm Ectoderm ZIC1neural tube, neural progenitors Mesoderm BRACH nascent mesoderm

Since many genes are expressed in more than one germ layer it is usefulto quantitatively compare expression levels of many genes within thesame experiment. SOX17 is expressed in definitive endoderm and to asmaller extent in visceral and parietal endoderm. SOX7 and AFP areexpressed in visceral endoderm at this early developmental time point.SPARC and TM are expressed in parietal endoderm and Brachyury isexpressed in early mesoderm.

Definitive endoderm cells were predicted to express high levels of SOX17mRNA and low levels of AFP and SOX7 (visceral endoderm), SPARC (parietalendoderm) and Brachyury (mesoderm). In addition, ZIC1 was used here tofurther rule out induction of early ectoderm. Finally, GATA4 and HNF3bwere expressed in both definitive and extra-embryonic endoderm, andthus, correlate with SOX17 expression in definitive endoderm (Table 1).A representative experiment is shown in FIGS. 11-14 which demonstrateshow the marker genes described in Table 1 correlate with each otheramong the various samples, thus highlighting specific patterns ofdifferentiation to definitive endoderm and extra-embryonic endoderm aswell as to mesodermal and neural cell types.

In view of the above data it is clear that increasing doses of activinresulted in increasing SOX17 gene expression. Further this SOX17expression predominantly represented definitive endoderm as opposed toextra-embryonic endoderm. This conclusion stems from the observationthat SOX17 gene expression was inversely correlated with AFP, SOX7, andSPARC gene expression.

Example 6 Directed Differentiation of Human ES Cells to DefinitiveEndoderm

Human ES cell cultures will randomly differentiate if they are culturedunder conditions that do not actively maintain their undifferentiatedstate. This heterogeneous differentiation results in production ofextra-embryonic endoderm cells comprised of both parietal and visceralendoderm (AFP, SPARC and SOX7 expression) as well as early ectodermaland mesodermal derivatives as marked by ZIC1 and Nestin (ectoderm) andBrachyury (mesoderm) expression. Definitive endoderm cell appearance hasnot traditionally been examined or specified for lack of specificantibody markers in ES cell cultures. As such, and by default, earlydefinitive endoderm production in ES cell cultures has not been wellstudied. Since no good antibody reagents for definitive endoderm cellshave been available, most of the characterization has focused onectoderm and extra-embryonic endoderm. Overall, there are significantlygreater numbers of extra-embryonic and neurectodermal cell types incomparison to SOX17^(hi) definitive endoderm cells in randomlydifferentiated ES cell cultures.

As undifferentiated hESC colonies expand on a bed of fibroblast feedersthe edges of the colony take on alternative morphologies that aredistinct from those cells residing within the interior of the colony.Many of these outer edge cells can be distinguished by their lessuniform, larger cell body morphology and by the expression of higherlevels of OCT4. It has been described that as ES cells begin todifferentiate they alter the levels of OCT4 expression up or downrelative to undifferentiated ES cells. Alteration of OCT4 levels aboveor below the undifferentiated threshold may signify the initial stagesof differentiation away from the pluripotent state.

When undifferentiated colonies were examined by SOX17immunocytochemistry, occasionally small 10-15-cell clusters ofSOX17-positive cells were detected at random locations on the peripheryand at the junctions between undifferentiated ESC colonies. As notedabove, these scattered pockets of outer colony edges appeared to be someof the first cells to differentiate away from the classical ESCmorphology as the colony expanded in size and became more crowded.Younger, smaller fully undifferentiated colonies (<1 mm; 4-5 days old)showed no SOX17 positive cells within or at the edges of the colonieswhile older, larger colonies (1-2 mm diameter, >5 days old) had sporadicisolated patches of SOX17 positive, AFP negative cells at the peripheryof some colonies or in regions interior to the edge that weredifferentiated away from classical hESC morphology described previously.Given that this was the first development of an effective SOX17antibody, definitive endoderm cells generated in such early“undifferentiated” ESC cultures have never been previously demonstrated.

Based on negative correlations of SOX17 and SPARC gene expression levelsby Q-PCR, the vast majority of these SOX17 positive, AFP negative cellswill be negative for parietal markers by antibody co-labeling. This wasspecifically demonstrated for TM-expressing parietal endoderm cells asshown in FIGS. 15A-B. Exposure to Nodal factors Activin A and B resultedin a dramatic decrease in the intensity to TM expression and the numberof TM positive cells. By triple labeling using SOX17, AFP and TMantibodies on an activin treated culture, clusters of SOX17 positivecells which were also negative for AFP and TM were observed (FIGS.16A-D). These are the first cellular demonstrations of SOX17 positivedefinitive endoderm cells in differentiating ESC cultures (FIGS. 16A-Dand 17).

With the SOX17 antibody and Q-PCR tools described above we have exploreda number of procedures capable of efficiently programming ESCs to becomeSOX17^(hi)/AFP^(lo)/SPARC/TM^(lo) definitive endoderm cells. We applieda variety of differentiation protocols aimed at increasing the numberand proliferative capacity of these cells as measured at the populationlevel by Q-PCR for SOX17 gene expression and at the level of individualcells by antibody labeling of SOX17 protein.

We were the first to analyze and describe the effect of TGFβ familygrowth factors, such as Nodal/activin/BMP, for use in creatingdefinitive endoderm cells from embryonic stem cells in in vitro cellcultures. In typical experiments, Activin A, Activin B, BMP orcombinations of these growth factors were added to cultures ofundifferentiated human stem cell line hESCyt-25 to begin thedifferentiation process.

As shown in FIG. 19, addition of Activin A at 100 ng/ml resulted in a19-fold induction of SOX17 gene expression vs. undifferentiated hESCs byday 4 of differentiation. Adding Activin B, a second member of theactivin family, together with Activin A, resulted in a 37-fold inductionover undifferentiated hESCs by day 4 of combined activin treatment.Finally, adding a third member of the TGFβ family from the Nodal/Activinand BMP subgroups, BMP4, together with Activin A and Activin B,increased the fold induction to 57 times that of undifferentiated hESCs(FIG. 19). When SOX17 induction with activins and BMP was compared to nofactor medium controls 5-, 10-, and 15-fold inductions resulted at the4-day time point. By five days of triple treatment with Activins A, Band BMP, SOX17 was induced more than 70 times higher than hESCs. Thesedata indicate that higher doses and longer treatment times of theNodal/activin TGFβ family members results in increased expression ofSOX17.

Nodal and related molecules Activin A, B and BMP facilitate theexpression of SOX17 and definitive endoderm formation in vivo or invitro. Furthermore, addition of BMP results in an improved SOX17induction possibly through the further induction of Cripto, the Nodalco-receptor.

We have demonstrated that the combination of Activins A and B togetherwith BMP4 result in additive increases in SOX17 induction and hencedefinitive endoderm formation. BMP4 addition for prolonged periods (>4days), in combination with Activin A and B may induce SOX17 in parietaland visceral endoderm as well as definitive endoderm. In someembodiments of the present invention, it is therefore valuable to removeBMP4 from the treatment within 4 days of addition.

To determine the effect of TGFβ factor treatment at the individual celllevel, a time course of TGFβ factor addition was examined using SOX17antibody labeling. As previously shown in FIGS. 10A-F, there was adramatic increase in the relative number of SOX17 labeled cells overtime. The relative quantification (FIG. 20) shows more than a 20-foldincrease in SOX17-labeled cells. This result indicates that both thenumbers of cells as well SOX17 gene expression level are increasing withtime of TGFβ factor exposure. As shown in FIG. 21, after four days ofexposure to Nodal, Activin A, Activin B and BMP4, the level of SOX17induction reached 168-fold over undifferentiated hESCs. FIG. 22 showsthat the relative number of SOX17-positive cells was also doseresponsive. Activin A doses of 100 ng/mL or more were capable ofpotently inducing SOX17 gene expression and cell number.

In addition to the TGFβ family members, the Wnt family of molecules mayplay a role in specification and/or maintenance of definitive endoderm.The use of Wnt molecules was also beneficial for the differentiation ofhESCs to definitive endoderm as indicted by the increased SOX17 geneexpression in samples that were treated with activins plus Wnt3a overthat of activins alone (FIG. 23).

All of the experiments described above were performed using tissueculture medium containing 10% serum with added factors. Surprisingly, wediscovered that the concentration of serum had an effect on the level ofSOX17 expression in the presence of added activins as shown in FIGS.24A-C. When serum levels were reduced from 10% to 2%, SOX17 expressiontripled in the presence of Activins A and B.

Finally, we demonstrated that activin induced SOX17⁺ cells divide inculture as depicted in FIGS. 25A-D. The arrows show cells labeled withSOX17/PCNA/DAPI that are in mitosis as evidenced by thePCNA/DAPI-labeled mitotic plate pattern and the phase contrast mitoticprofile.

Example 7 Chemokine Receptor 4 (CXCR4) Expression Correlates withMarkers for Definitive Endoderm and not Markers for Mesoderm, Ectodermor Visceral Endoderm

As described above, ESCs can be induced to differentiate to thedefinitive endoderm germ layer by the application of cytokines of theTGFβ family and more specifically of the activin/nodal subfamily.Additionally, we have shown that the proportion of fetal bovine serum(FBS) in the differentiation culture medium effects the efficiency ofdefinitive endoderm differentiation from ESCs. This effect is such thatat a given concentration of activin A in the medium, higher levels ofFBS will inhibit maximal differentiation to definitive endoderm. In theabsence of exogenous activin A, differentiation of ESCs to thedefinitive endoderm lineage is very inefficient and the FBSconcentration has much milder effects on the differentiation process ofESCs.

In these experiments, hESCs were differentiated by growing in RPMImedium (Invitrogen, Carlsbad, Calif.; cat#61870-036) supplemented with0.5%, 2.0% or 10% FBS and either with or without 100 ng/mL activin A for6 days. In addition, a gradient of FBS ranging from 0.5% to 2.0% overthe first three days of differentiation was also used in conjunctionwith 100 ng/mL of activin A. After the 6 days, replicate samples werecollected from each culture condition and analyzed for relative geneexpression by real-time quantitative PCR. The remaining cells were fixedfor immunofluorescent detection of SOX17 protein.

The expression levels of CXCR4 varied dramatically across the 7 cultureconditions used (FIG. 26). In general, CXCR4 expression was high inactivin A treated cultures (A100) and low in those which did not receiveexogenous activin A (NF). In addition, among the A100 treated cultures,CXCR4 expression was highest when FBS concentration was lowest. Therewas a remarkable decrease in CXCR4 level in the 10% FBS condition suchthat the relative expression was more in line with the conditions thatdid not receive activin A (NF).

As described above, expression of the SOX17, GSC, MIXL1, and HNF3β genesis consistent with the characterization of a cell as definitiveendoderm. The relative expression of these four genes across the 7differentiation conditions mirrors that of CXCR4 (FIGS. 27A-D). Thisdemonstrates that CXCR4 is also a marker of definitive endoderm.

Ectoderm and mesoderm lineages can be distinguished from definitiveendoderm by their expression of various markers. Early mesodermexpresses the genes Brachyury and MOX1 while nascent neuro-ectodermexpresses SOX1 and ZIC1. FIGS. 28A-D demonstrate that the cultures whichdid not receive exogenous activin A were preferentially enriched formesoderm and ectoderm gene expression and that among the activin Atreated cultures, the 10% FBS condition also had increased levels ofmesoderm and ectoderm marker expression. These patterns of expressionwere inverse to that of CXCR4 and indicated that CXCR4 was not highlyexpressed in mesoderm or ectoderm derived from ESCs at thisdevelopmental time period.

Early during mammalian development, differentiation to extra-embryoniclineages also occurs. Of particular relevance here is thedifferentiation of visceral endoderm that shares the expression of manygenes in common with definitive endoderm, including SOX17. Todistinguish definitive endoderm from extra-embryonic visceral endodermone should examine a marker that is distinct between these two. SOX7represents a marker that is expressed in the visceral endoderm but notin the definitive endoderm lineage. Thus, culture conditions thatexhibit robust SOX17 gene expression in the absence of SOX7 expressionare likely to contain definitive and not visceral endoderm. It is shownin FIG. 28E that SOX7 was highly expressed in cultures that did notreceive activin A, SOX7 also exhibited increased expression even in thepresence of activin A when FBS was included at 10%. This pattern is theinverse of the CXCR4 expression pattern and suggests that CXCR4 is nothighly expressed in visceral endoderm.

The relative number of SOX17 immunoreactive (SOX17⁺) cells present ineach of the differentiation conditions mentioned above was alsodetermined When hESCs were differentiated in the presence of high doseactivin A and low FBS concentration (0.5%-2.0%) SOX17⁺ cells wereubiquitously distributed throughout the culture. When high dose activinA was used but FBS was included at 10% (v/v), the SOX17⁺ cells appearedat much lower frequency and always appeared in isolated clusters ratherthan evenly distributed throughout the culture (FIGS. 29A and C as wellas B and E). A further decrease in SOX17⁺ cells was seen when noexogenous activin A was used. Under these conditions the SOX17⁺ cellsalso appeared in clusters and these clusters were smaller and much morerare than those found in the high activin A, low FBS treatment (FIGS. 29C and F). These results demonstrate that the CXCR4 expression patternsnot only correspond to definitive endoderm gene expression but also tothe number of definitive endoderm cells in each condition.

Example 8 Differentiation Conditions that Enrich for Definitive EndodermIncrease the Proportion of CXCR4 Positive Cells

The dose of activin A also effects the efficiency at which definitiveendoderm can be derived from ESCs. This example demonstrates thatincreasing the dose of activin A increases the proportion of CXCR4⁺cells in the culture.

hESCs were differentiated in RPMI media supplemented with 0.5%-2% FBS(increased from 0.5% to 1.0% to 2.0% over the first 3 days ofdifferentiation) and either 0, 10, or 100 ng/mL of activin A. After 7days of differentiation the cells were dissociated in PBS withoutCa²⁺/Mg²⁺ containing 2% FBS and 2 mM (EDTA) for 5 minutes at roomtemperature. The cells were filtered through 35 um nylon filters,counted and pelleted. Pellets were resuspended in a small volume of 50%human serum/50% normal donkey serum and incubated for 2 minutes on iceto block non-specific antibody binding sites. To this, 1 uL of mouseanti-CXCR4 antibody (Abeam, cat# ab10403-100) was added per 50 uL(containing approximately 10⁵ cells) and labeling proceeded for 45minutes on ice. Cells were washed by adding 5 mL of PBS containing 2%human serum (buffer) and pelleted. A second wash with 5 mL of buffer wascompleted then cells were resuspended in 50 uL buffer per 10⁵ cells.Secondary antibody (FITC conjugated donkey anti-mouse; JacksonImmunoResearch, cat#715-096-151) was added at 5 ug/mL finalconcentration and allowed to label for 30 minutes followed by two washesin buffer as above. Cells were resuspended at 5×10⁶ cells/mL in bufferand analyzed and sorted using a FACS Vantage (Beckton Dickenson) by thestaff at the flow cytometry core facility (The Scripps ResearchInstitute). Cells were collected directly into RLT lysis buffer (Qiagen)for subsequent isolation of total RNA for gene expression analysis byreal-time quantitative PCR.

The number of CXCR4⁺ cells as determined by flow cytometry were observedto increase dramatically as the dose of activin A was increased in thedifferentiation culture media (FIGS. 30A-C). The CXCR4⁺ cells were thosefalling within the R4 gate and this gate was set using a secondaryantibody-only control for which 0.2% of events were located in the R4gate. The dramatically increased numbers of CXCR4⁺ cells correlates witha robust increase in definitive endoderm gene expression as activin Adose is increased (FIGS. 31A-D).

Example 9 Isolation of CXCR4 Positive Cells Enriches for DefinitiveEndoderm Gene Expression and Depletes Cells Expressing Markers ofMesoderm, Ectoderm and Visceral Endoderm

The CXCR4⁺ and CXCR4⁻ cells identified in Example 8 above were collectedand analyzed for relative gene expression and the gene expression of theparent populations was determined simultaneously.

The relative levels of CXCR4 gene expression was dramatically increasedwith increasing dose of activin A (FIG. 32). This correlated very wellwith the activin A dose-dependent increase of CXCR4⁺ cells (FIGS.30A-C). It is also clear that isolation of the CXCR4⁺ cells from eachpopulation accounted for nearly all of the CXCR4 gene expression in thatpopulation. This demonstrates the efficiency of the FACS method forcollecting these cells.

Gene expression analysis revealed that the CXCR4⁺ cells contain not onlythe majority of the CXCR4 gene expression, but they also contained othergene expression for markers of definitive endoderm. As shown in FIGS.31A-D, the CXCR4⁺ cells were further enriched over the parent A100population for SOX17, GSC, HNF3B, and MIXL1. In addition, the CXCR4⁻fraction contained very little gene expression for these definitiveendoderm markers. Moreover, the CXCR4⁺ and CXCR4⁻ populations displayedthe inverse pattern of gene expression for markers of mesoderm, ectodermand extra-embryonic endoderm. FIGS. 33A-D shows that the CXCR4⁺ cellswere depleted for gene expression of Brachyury, MOX1, ZIC1, and SOX7relative to the A100 parent population. This A100 parent population wasalready low in expression of these markers relative to the low dose orno activin A conditions. These results show that the isolation of CXCR4⁺cells from hESCs differentiated in the presence of high activin A yieldsa population that is highly enriched for and substantially puredefinitive endoderm.

Example 10 Quantitation of Definitive Endoderm Cells in a CellPopulation Using CXCR4

To confirm the quantitation of the proportion of definitive endodermcells present in a cell culture or cell population as determinedpreviously herein and as determined in U.S. Provisional PatentApplication No. 60/532,004, entitled DEFINITIVE ENDODERM, filed Dec. 23,2003, the disclosure of which is incorporated herein by reference in itsentirety, cells expressing CXCR4 and other markers of definitiveendoderm were analyzed by FACS.

Using the methods such as those described in the above Examples, hESCswere differentiated to produce definitive endoderm. In particular,increase yield and purity expressed in differentiating cell cultures,the serum concentration of the medium was controlled as follows: 0.2%FBS on day 1, 1.0% FBS on day 2 and 2.0% FBS on days 3-6. Differentiatedcultures were sorted by FACS using three cell surface epitopes,E-Cadherin, CXCR4, and Thrombomodulin. Sorted cell populations were thenanalyzed by Q-PCR to determine relative expression levels of markers fordefinitive and extraembryonic-endoderm as well as other cell types.CXCR4 sorted cells taken from optimally differentiated cultures resultedin the isolation of definitive endoderm cells that were >98% pure.

Table 2 shows the results of a marker analysis for a definitive endodermculture that was differentiated from hESCs using the methods describedherein.

TABLE 2 Composition of Definitive Endoderm Cultures Percent PercentPercent Percent of Definitive Extraembryonic hES Marker(s) cultureEndoderm endododerm cells SOX17 70-80 100 Thrombomodulin <2 0 75 AFP <10 25 CXCR4 70-80 100 0 ECAD 10 0 100 other (ECAD neg.) 10-20 Total 100 100 100 100

In particular, Table 2 indicates that CXCR4 and SOX17 positive cells(endoderm) comprised from 70%-80% of the cells in the cell culture. Ofthese SOX17-expressing cells, less than 2% expressed TM (parietalendoderm) and less than 1% expressed AFP (visceral endoderm). Aftersubtracting the proportion of TM-positive and AFP-positive cells(combined parietal and visceral endoderm; 3% total) from the proportionof SOX17/CXCR4 positive cells, it can be seen that about 67% to about77% of the cell culture was definitive endoderm. Approximately 10% ofthe cells were positive for E-Cadherin (ECAD), which is a marker forhESCs, and about 10-20% of the cells were of other cell types.

We have discovered that the purity of definitive endoderm in thedifferentiating cell cultures that are obtained prior to FACS separationcan be improved as compared to the above-described low serum procedureby maintaining the FBS concentration at <0.5% throughout the 5-6 daydifferentiation procedure. However, maintaining the cell culture at<0.5% throughout the 5-6 day differentiation procedure also results in areduced number of total definitive endoderm cells that are produced.

Definitive endoderm cells produced by methods described herein have beenmaintained and expanded in culture in the presence of activin forgreater than 50 days without appreciable differentiation. In such cases,SOX17, CXCR4, MIXL1, GATA4, HNF3 f3 expression is maintained over theculture period. Additionally, TM, SPARC, OCT4, AFP, SOX7, ZIC1 and BRACHwere not detected in these cultures. It is likely that such cells can bemaintained and expanded in culture for substantially longer than 50 dayswithout appreciable differentiation.

Example 11 Additional Marker of Definitive Endoderm Cells

In the following experiment, RNA was isolated from purified definitiveendoderm and human embryonic stem cell populations. Gene expression wasthen analyzed by gene chip analysis of the RNA from each purifiedpopulation. Q-PCR was also performed to further investigate thepotential of genes expressed in definitive endoderm, but not inembryonic stem cells, as a marker for definitive endoderm.

Human embryonic stem cells (hESCs) were maintained in DMEM/F12 mediasupplemented with 20% KnockOut Serum Replacement, 4 ng/mL recombinanthuman basic fibroblast growth factor (bFGF), 0.1 mM 2-mercaptoethanol,L-glutamine, non-essential amino acids and penicillin/streptomycin.hESCs were differentiated to definitive endoderm by culturing for 5 daysin RPMI media supplemented with 100 ng/mL of recombinant human activinA, fetal bovine serum (FBS), and penicillin/streptomycin. Theconcentration of FBS was varied each day as follows: 0.1% (first day),0.2% (second day), 2% (days 3-5).

Cells were isolated by fluorescence activated cell sorting (FACS) inorder to obtain purified populations of hESCs and definitive endodermfor gene expression analysis. Immuno-purification was achieved for hESCsusing SSEA4 antigen (R&D Systems, cat# FAB1435P) and for definitiveendoderm using CXCR4 (R&D Systems, cat# FAB170P). Cells were dissociatedusing trypsin/EDTA (Invitrogen, cat#25300-054), washed in phosphatebuffered saline (PBS) containing 2% human serum and resuspended in 100%human serum on ice for 10 minutes to block non-specific binding.Staining was carried out for 30 minutes on ice by adding 200 uL ofphycoerythrin-conjugated antibody to 5×10⁶ cells in 800 uL human serum.Cells were washed twice with 8 mL of PBS buffer and resuspended in 1 mLof the same. FACS isolation was carried out by the core facility of TheScripps Research Institute using a FACS Vantage (BD Biosciences). Cellswere collected directly into RLT lysis buffer and RNA was isolated byRNeasy according to the manufacturers instructions (Qiagen).

Purified RNA was submitted in duplicate to Expression Analysis (Durham,N.C.) for generation of the expression profile data using the Affymetrixplatform and U133 Plus 2.0 high-density oligonucleotide arrays. Datapresented is a group comparison that identifies genes differentiallyexpressed between the two populations, hESCs and definitive endoderm.Genes that exhibited a robust upward change in expression level overthat found in hESCs were selected as new candidate markers that arehighly characteristic of definitive endoderm. Select genes were assayedby Q-PCR, as described above, to verify the gene expression changesfound on the gene chip and also to investigate the expression pattern ofthese genes during a time course of hESC differentiation.

FIGS. 34A-M show the gene expression results for certain markers.Results are displayed for cell cultures analyzed 1, 3 and 5 days afterthe addition of 100 ng/ml activin A, CXCR4-expressing definitiveendoderm cells purified at the end of the five day differentiationprocedure (CXDE), and in purified human embryonic stem cells (HESC). Acomparison of FIGS. 34C and G-M demonstrates that the six marker genes,FGF17, VWF, CALCR, FOXQ1, CMKOR1 and CRIP1, exhibit an expressionpattern that is almost identical to each other and which is alsoidentical to the pattern of expression of CXCR4 and SOX17/50×7. Asdescribed previously, SOX17 is expressed in both the definitive endodermas well as in the SOX7-expressing extra-embryonic endoderm. Since SOX7is not expressed in the definitive endoderm, the ratio of SOX17/50X7provides a reliable estimate of definitive endoderm contribution to theSOX17 expression witnessed in the population as a whole. The similarityof panels G-L and M to panel C indicates that FGF17, VWF, CALCR, FOXQ1,CMKOR1 and CRIP1 are likely markers of definitive endoderm and that theyare not significantly expressed in extra-embryonic endoderm cells.

It will be appreciated that the Q-PCR results described herein can befurther confirmed by ICC.

The methods, compositions, and devices described herein are presentlyrepresentative of preferred embodiments and are exemplary and are notintended as limitations on the scope of the invention. Changes thereinand other uses will occur to those skilled in the art which areencompassed within the spirit of the invention and are defined by thescope of the disclosure. Accordingly, it will be apparent to one skilledin the art that varying substitutions and modifications may be made tothe invention disclosed herein without departing from the scope andspirit of the invention.

As used in the claims below and throughout this disclosure, by thephrase “consisting essentially of” is meant including any elementslisted after the phrase, and limited to other elements that do notinterfere with or contribute to the activity or action specified in thedisclosure for the listed elements. Thus, the phrase “consistingessentially of” indicates that the listed elements are required ormandatory, but that other elements are optional and may or may not bepresent depending upon whether or not they affect the activity or actionof the listed elements.

REFERENCES

Numerous literature and patent references have been cited in the presentpatent application. Each and every reference that cited in this patentapplication is incorporated by reference herein in its entirety.

For some references, the complete citation is in the body of the text.For other references the citation in the body of the text is by authorand year, the complete citation being as follows:

-   Alexander, J., Rothenberg, M., Henry, G. L., and Stainier, D. Y.    (1999). Casanova plays an early and essential role in endoderm    formation in zebrafish. Dev Biol 215, 343-357.-   Alexander, J., and Stainier, D. Y. (1999). A molecular pathway    leading to endoderm formation in zebrafish. Curr Biol 9, 1147-1157.-   Aoki, T. O., Mathieu, J., Saint-Etienne, L., Rebagliati, M. R.,    Peyrieras, N., and Rosa, F. M. (2002). Regulation of nodal    signalling and mesendoderm formation by TARAM-A, a TGFbeta-related    type I receptor. Dev Biol 241, 273-288.-   Beck, S., Le Good, J. A., Guzman, M., Ben Haim, N., Roy, K.,    Beermann, F, and Constam, D. B. (2002). Extra-embryonic proteases    regulate Nodal signalling during gastrulation. Nat Cell Biol 4,    981-985.-   Beddington, R. S., Rashbass, P., and Wilson, V. (1992). Brachyury—a    gene affecting mouse gastrulation and early organogenesis. Dev    Suppl, 157-165.-   Bongso, A., Fong, C. Y., Ng, S. C., and Ratnam, S. (1994). Isolation    and culture of inner cell mass cells from human blastocysts. Hum    Reprod 9, 2110-2117.-   Chang, H., Brown, C. W., and Matzuk, M. M. (2002). Genetic analysis    of the mammalian transforming growth factor-beta superfamily. Endocr    Rev 23, 787-823.-   Conlon, F. L., Lyons, K. M., Takaesu, N., Barth, K. S., Kispert, A.,    Herrmann, B., and Robertson, E. J. (1994). A primary requirement for    nodal in the formation and maintenance of the primitive streak in    the mouse. Development 120, 1919-1928.-   Dougan, S. T., Warga, R. M., Kane, D. A., Schier, A. F., and    Talbot, W. S. (2003). The role of the zebrafish nodal-related genes    squint and cyclops in patterning of mesendoderm. Development 130,    1837-1851.-   Feldman, B., Gates, M. A., Egan, E. S., Dougan, S. T., Rennebeck,    G., Sirotkin, H. I., Schier, A. F., and Talbot, W. S. (1998).    Zebrafish organizer development and germ-layer formation require    nodal-related signals. Nature 395, 181-185.-   Feng, Y., Broder, C. C., Kennedy, P. E., and Berger, E. A. (1996).    HIV-1 entry cofactor: functional cDNA cloning of a    seven-transmembrane, G protein-coupled receptor. Science 272,    872-877.-   Futaki, S., Hayashi, Y., Yamashita, M., Yagi, K., Bono, H.,    Hayashizaki, Y., Okazaki, Y., and Sekiguchi, K. (2003). Molecular    basis of constitutive production of basement membrane components:    Gene expression profiles of engelbreth-hohn-swarm tumor and F9    embryonal carcinoma cells. J Biol Chem.-   Grapin-Botton, A., and Melton, D. A. (2000). Endoderm development:    from patterning to organogenesis. Trends Genet 16, 124-130.-   Harris, T. M., and Childs, G. (2002). Global gene expression    patterns during differentiation of F9 embryonal carcinoma cells into    parietal endoderm. Funct Integr Genomics 2, 105-119.-   Hogan, B. L. (1996). Bone morphogenetic proteins in development.    Curr Opin Genet Dev 6, 432-438.-   Hogan, B. L. (1997). Pluripotent embryonic cells and methods of    making same (U.S.A., Vanderbilt University).-   Howe, C. C., Overton, G. C., Sawicki, J., Softer, D., Stein, P., and    Strickland, S. (1988). Expression of SPARC/osteonectin transcript in    murine embryos and gonads. Differentiation 37, 20-25.-   Hudson, C., Clements, D., Friday, R. V., Stott, D., and    Woodland, H. R. (1997). Xsox17alpha and -beta mediate endoderm    formation in Xenopus. Cell 91, 397-405.-   Imada, M., Imada, S., Iwasaki, H., Kume, A., Yamaguchi, H., and    Moore, E. E. (1987). Fetomodulin: marker surface protein of fetal    development which is modulatable by cyclic AMP. Dev Biol 122,    483-491.-   Kanai-Azuma, M., Kanai, Y., Gad, J. M., Tajima, Y., Taya, C.,    Kurohmaru, M., Sanai, Y., Yonekawa, H., Yazaki, K., Tam, P. P., and    Hayashi, Y. (2002). Depletion of definitive gut endoderm in    Sox17-null mutant mice. Development 129, 2367-2379.-   Katoh, M. (2002). Expression of human SOX7 in normal tissues and    tumors. Int J Mol Med 9, 363-368.-   Kikuchi, Y., Agathon, A., Alexander, J., Thisse, C., Waldron, S.,    Yelon, D., Thisse, B., and Stainier, D. Y. (2001). casanova encodes    a novel Sox-related protein necessary and sufficient for early    endoderm formation in zebrafish. Genes Dev 15, 1493-1505.-   Kim, C. H., and Broxmeyer, H. E. (1999). Chemokines: signal lamps    for trafficking of T and B cells for development and effector    function. J Leukoc Biol 65, 6-15.-   Kimelman, D., and Griffin, K. J. (2000). Vertebrate mesendoderm    induction and patterning. Curr Opin Genet Dev 10, 350-356.-   Kubo A, Shinozaki K, Shannon J M, Kouskoff V, Kennedy M, Woo S,    Fehling H J, Keller G. (2004) Development of definitive endoderm    from embryonic stem cells in culture. Development. 131, 1651-62.-   Kumar, A., Novoselov, V., Celeste, A. J., Wolfman, N. M., ten Dijke,    P., and Kuehn, M. R. (2001). Nodal signaling uses activin and    transforming growth factor-beta receptor-regulated Smads. J Biol    Chem 276, 656-661.-   Labosky, P. A., Barlow, D. P., and Hogan, B. L. (1994a). Embryonic    germ cell lines and their derivation from mouse primordial germ    cells. Ciba Found Symp 182, 157-168; discussion 168-178.-   Labosky, P. A., Barlow, D. P., and Hogan, B. L. (1994b). Mouse    embryonic germ (EG) cell lines: transmission through the germline    and differences in the methylation imprint of insulin-like growth    factor 2 receptor (Igf2r) gene compared with embryonic stem (ES)    cell lines. Development 120, 3197-3204.-   Lickert, H., Kutsch, S., Kanzler, B., Tamai, Y., Taketo, M. M., and    Kemler, R. (2002). Formation of multiple hearts in mice following    deletion of beta-catenin in the embryonic endoderm. Dev Cell 3,    171-181.-   Lu, C. C., Brennan, J., and Robertson, E. J. (2001). From    fertilization to gastrulation: axis formation in the mouse embryo.    Curr Opin Genet Dev 11, 384-392.-   Ma, Q., Jones, D., and Springer, T. A. (1999). The chemokine    receptor CXCR4 is required for the retention of B lineage and    granulocytic precursors within the bone marrow microenvironment.    Immunity 10, 463-471.-   McGrath K E, Koniski A D, Maltby K M, McGann J K, Palis J. (1999)    Embryonic expression and function of the chemokine SDF-1 and its    receptor, CXCR4. Dev Biol. 213, 442-56.-   Miyazono, K., Kusanagi, K., and Inoue, H. (2001). Divergence and    convergence of TGF-beta/BMP signaling. J Cell Physiol 187, 265-276.-   Nagasawa, T., Hirota, S., Tachibana, K., Takakura, N., Nishikawa,    S., Kitamura, Y., Yoshida, N., Kikutani, H., and Kishimoto, T.    (1996). Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis    in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382, 635-638.-   Niwa, H. (2001). Molecular mechanism to maintain stem cell renewal    of ES cells. Cell Struct Funct 26, 137-148.-   Ogura, H., Aruga, J., and Mikoshiba, K. (2001). Behavioral    abnormalities of Zic1 and Zic2 mutant mice: implications as models    for human neurological disorders. Behav Genet 31, 317-324.-   Reubinoff, B. E., Pera, M. F., Fong, C. Y., Trounson, A., and    Bongso, A. (2000). Embryonic stem cell lines from human blastocysts:    somatic differentiation in vitro. Nat Biotechnol 18, 399-404.-   Rodaway, A., and Patient, R. (2001). Mesendoderm. an ancient germ    layer? Cell 105, 169-172.-   Rodaway, A., Takeda, H., Koshida, S., Broadbent, J., Price, B.,    Smith, J. C., Patient, R., and Holder, N. (1999). Induction of the    mesendoderm in the zebrafish germ ring by yolk cell-derived TGF-beta    family signals and discrimination of mesoderm and endoderm by FGF.    Development 126, 3067-3078.-   Rohr, K. B., Schulte-Merker, S., and Tautz, D. (1999). Zebrafish zic    1 expression in brain and somites is affected by BMP and hedgehog    signalling. Mech Dev 85, 147-159.-   Schier, A. F. (2003). Nodal signaling in vertebrate development.    Annu Rev Cell Dev Biol 19, 589-621.-   Schoenwolf, G. C., and Smith, J. L. (2000). Gastrulation and early    mesodermal patterning in vertebrates. Methods Mol Biol 135, 113-125.-   Shamblott, M. J., Axehnan, J, Wang, S., Bugg, E. M., Littlefield, J.    W., Donovan, P. J., Blumenthal, P. D., Huggins, G. R., and    Gearhart, J. D. (1998). Derivation of pluripotent stem cells from    cultured human primordial germ cells. Proc Natl Acad Sci USA 95,    13726-13731.-   Shapiro, A. M., Lakey, J. R., Ryan, E. A., Korbutt, G. S., Toth, E.,    Warnock, G. L., Kneteman, N. M., and Rajotte, R. V. (2000). Islet    transplantation in seven patients with type 1 diabetes mellitus    using a glucocorticoid-free immunosuppressive regimen. N Engl J Med    343, 230-238.-   Shapiro, A. M., Ryan, E. A., and Lakey, J. R. (2001a). Pancreatic    islet transplantation in the treatment of diabetes mellitus. Best    Pract Res Clin Endocrinol Metab 15, 241-264.-   Shapiro, J., Ryan, E., Warnock, G. L., Kneteman, N. M., Lakey, J.,    Korbutt, G. S., and Rajotte, R. V. (2001b). Could fewer islet cells    be transplanted in type 1 diabetes? Insulin independence should be    dominant force in islet transplantation. Bmj 322, 861.-   Shiozawa, M., Hiraoka, Y., Komatsu, N., Ogawa, M., Sakai, Y., and    Aiso, S. (1996). Cloning and characterization of Xenopus laevis    xSox7 cDNA. Biochim Biophys Acta 1309, 73-76.-   Smith, J. (1997). Brachyury and the T-box genes. Curr Opin Genet Dev    7, 474-480.-   Smith, J. C., Armes, N. A., Conlon, F. L., Tada, M., Umbhauer, M.,    and Weston, K. M. (1997). Upstream and downstream from Brachyury, a    gene required for vertebrate mesoderm formation. Cold Spring Harb    Symp Quant Biol 62, 337-346.-   Takash, W., Canizares, J., Bonneaud, N., Poulat, F., Mattei, M. G.,    Jay, P., and Berta, P. (2001). SOX7 transcription factor: sequence,    chromosomal localisation, expression, transactivation and    interference with Wnt signalling. Nucleic Acids Res 29, 4274-4283.-   Taniguchi, K., Hiraoka, Y., Ogawa, M., Sakai, Y., Kido, S., and    Aiso, S. (1999). Isolation and characterization of a mouse    SRY-related cDNA, mSox7. Biochim Biophys Acta 1445, 225-231.-   Technau, U. (2001). Brachyury, the blastopore and the evolution of    the mesoderm. Bioessays 23, 788-794.-   Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A.,    Swiergiel, J. J., Marshall, V. S., and Jones, J. M. (1998).    Embryonic stem cell lines derived from human blastocysts. Science    282, 1145-1147.-   Tremblay, K. D., Hoodless, P. A., Bikoff, E. K., and    Robertson, E. J. (2000). Formation of the definitive endoderm in    mouse is a Smad2-dependent process. Development 127, 3079-3090.-   Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N.,    De Paepe, A., and Speleman, F. (2002). Accurate normalization of    real-time quantitative RT-PCR data by geometric averaging of    multiple internal control genes. Genome Biol 3, RESEARCH0034.-   Varlet, I., Collignon, J., and Robertson, E. J. (1997). nodal    expression in the primitive endoderm is required for specification    of the anterior axis during mouse gastrulation. Development 124,    1033-1044.-   Vincent, S. D., Dunn, N. R., Hayashi, S., Norris, D. P., and    Robertson, E. J. (2003). Cell fate decisions within the mouse    organizer are governed by graded Nodal signals. Genes Dev 17,    1646-1662.-   Weiler-Guettler, H., Aird, W. C., Rayburn, H., Husain, M., and    Rosenberg, R. D. (1996). Developmentally regulated gene expression    of thrombomodulin in postimplantation mouse embryos. Development    122, 2271-2281.-   Weiler-Guettler, H., Yu, K., Soff, G., Gudas, L. J., and    Rosenberg, R. D. (1992). Thrombomodulin gene regulation by cAMP and    retinoic acid in F9 embryonal carcinoma cells. Proceedings Of The    National Academy Of Sciences Of The United States Of America 89,    2155-2159.-   Wells, J. M., and Melton, D. A. (1999). Vertebrate endoderm    development. Annu Rev Cell Dev Biol 15, 393-410.-   Wells, J. M., and Melton, D. A. (2000). Early mouse endoderm is    patterned by soluble factors from adjacent germ layers. Development    127, 1563-1572.-   Willison, K. (1990). The mouse Brachyury gene and mesoderm    formation. Trends Genet 6, 104-105.-   Zhao, G. Q. (2003). Consequences of knocking out BMP signaling in    the mouse. Genesis 35, 43-56.-   Zhou, X., Sasaki, H., Lowe, L., Hogan, B. L., and Kuehn, M. R.    (1993). Nodal is a novel TGF-beta-like gene expressed in the mouse    node during gastrulation. Nature 361, 543-547.

What is claimed is:
 1. An in vitro cell culture comprising humandefinitive endoderm cells in a medium comprising serum, wherein lessthan about 5% (v/v) of the medium is serum.
 2. The cell culture of claim1, wherein the medium further comprises a TGFβ superfamily growthfactor.
 3. The cell culture of claim 1, wherein the medium furthercomprises a TGFβ superfamily growth factor and a Wnt family member. 4.The cell culture of claim 1, wherein less than about 2% (v/v) of themedium is serum.
 5. The cell culture of claim 1, wherein less than about0.2% (v/v) of the medium is serum.
 6. The cell culture of claim 1,wherein the medium does not comprise serum replacement.
 7. The cellculture of claim 1, wherein the human definitive endoderm cells areproduced by a method comprising: (a) culturing a population ofpluripotent human cells in a growth medium comprising serum and a TGFβsuperfamily growth factor, thereby producing human definitive endodermcells, wherein less than about 5% (v/v) of the growth medium is serum.8. The cell culture of claim 7, wherein said growth medium does notcomprise serum replacement.
 9. The cell culture of claim 7, wherein saidTGFβ superfamily growth factor in said growth medium is selected fromthe group consisting of Nodal, activin A and activin B.
 10. The cellculture of claim 7, wherein said TGFβ superfamily growth factor in saidgrowth medium is activin A.
 11. The cell culture of claim 7, wherein atleast 10 ng/ml activin A is present in said growth medium.
 12. The cellculture of claim 7, wherein at least 100 ng/ml activin A is present insaid growth medium.
 13. The cell culture of claim 7, wherein said growthmedium further comprises a Wnt family member.
 14. The cell culture ofclaim 7, wherein the Wnt family member is Wnt3a.
 15. The cell culture ofclaim 7, wherein the growth medium comprises less than 2% serum.
 16. Thecell culture of claim 7, wherein the growth medium comprises less than0.2% serum.
 17. The cell culture of claim 7, wherein the methodcomprises, prior to step (a), culturing the pluripotent human cells in afirst growth medium comprising no serum for about 24 hours.
 18. The cellculture of claim 17, wherein the method comprises, prior to step (a) andafter said culturing in said first growth medium, culturing thepluripotent human cells in a series of additional growth mediumscomprising successively increasing concentrations of serum.
 19. An invitro cell culture comprising human definitive endoderm cells in amedium comprising serum and a TGFβ superfamily growth factor, whereinless than about 5% (v/v) of the medium is serum.
 20. An in vitro cellculture comprising human definitive endoderm cells in a mediumcomprising serum, a TGFβ superfamily growth factor and a Wnt familymember, wherein less than about 5% (v/v) of the medium is serum.